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perfusionDscintigraphyDinDhumans.DAdenosineDcanDalsoDinduceDangiogenesisDthroughD
directDandDindirectDmitogenicDeffectsDonDvascularDcells.DTheDmainDproGangiogenicD
actionsDofDadenosineDhaveDbeenDtrackedDdownDtoDitsDabilityDtoDregulateDtheDproductionD
ofDproGDorDantiGangiogenicDsubstancesDfromDvascularDcellsDthroughDhypoxiaGinducibleD
factorsD(HIFs)DsuchDasDbasicDfibroblastDgrowthDfactorD(bFGF)DandDvascularDendothelialD
growthDfactorD(VEGF)DwithinDtheDmicroenvironmentDofDhypoxicDtissues.DAdenosineD
alsoDprotectsDtheDmyocardiumD(asDwellDasDotherDtissues)DfromDhypoxiaDandDreperfusionD
injuryDthroughDischaemicDpreconditioningD(recentlyDreviewedDbyD asDandD as,D2008).D
InDaddition,DadenosineDshowsDanthiarrythmicDeffectsD(reductionDofDbothDheartDrateDandD
contractility)DandDitDisDintravenouslyDadministeredDtoDrestoreDnormalDheartDrhythmDinD
patientsDwithDparoxysmalDsupraventricularDtachycardia.DHowever,DforDconditionsD
requiringDrepeatedDapplicationsDmoreDselectiveDagonistsDforDtheDA1DsubtypeDofDARDareD
requiredDtoDreduceDundesirableDeffectsDinDotherDorgansDandDsystems. 


Fig*2+*Effects*of*adenosine*in*various*organs*and*systems,*during*inflammation*and*tumor*progression*
D
D
ExtracellularDadenosineDaffectsDseveralDkidneyDfunctionsDbothDatDtheDvascularDandD
tubularDlevel.DFirst,DthisDnucleosideDcanDsignificantlyDreduceDtheDglomerularDfiltrationD
rateDbyDactivatingDtheDA1ARDonDafferentDarteriolesD(HansenDandDSchnermann,D2003).D
Second,DadenosineGinducedDvasodilationDthroughDtheDA2AARDinDtheDdeepDcortexDandD
medullaDcontributesDtoDminimizeDmedullaryDinjuryDduringDhypoxicDepisodes.DThird,D
ARDactivationDhasDbeenDshownDtoDinhibitDtheDsecretionDofDreninD(EdlundDetDal.,D1994).D
Fourth,DadenosineDhasDbeenDshownDtoDpreventDischemiaGreperfusionDinjuryDinDtheD
kidneyDthoughDischemicDpreconditioningD(LeeDandDEmala,D2000).D
AdenosineDhasDalsoDbeenDimplicatedDinDglucoseDmetabolismDandDlipolysis.DActivationD
ofDA1ARDhasDbeenDassociatedDwithDanDincreaseDinDplasmaDinsulin,DincreaseDinDinsulinD
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Roles of adenosine in inflammation 
resolution (acute) 
Roles of adenosine in inflammation 
perpetuation (chronic) 
• Prevention of leukocyte trafficking 
• Reduction of macrophage activation 
• Downregulation of pro-inflammatory 
cytokines in several immune cell types 
• Upregulation of anti-inflammatory IL-10 
in macrophages 
• Reduction of platelet and lymphocyte 
activation 
• Upregulation of pro-inflammatory 
cytokines (i.e. IL-4, IL-6, IL-8, IL-13, 
MCP-1) 
• Fibroblast to myofibrobalst 
differentiation (pro-fibrotic) 
• Tissue remodelling (i.e. protease-
mediated airway destruction) 
• Mucus metaplasia 
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AR subtype G protein Downstream signalling Reference 
A1AR Gi  cAMP 
 PLC 
 Ca2+ Channels 
 K+ Channels 
(Londos et al., 1980) 
(Rogel et al., 2005) 
(Fredholm et al., 2001) 
(Belardinelli et al., 1995) 
A2AAR Gs * 
 
 cAMP 
 PLC 
 IP3 
(Fresco et al., 2004) 
 
(Offermanns and Simon, 1995) 
A2BAR Gs  cAMP 
 IP3 
(Brackett and Daly, 1994) 
Gq  PLC (Feoktistov and Biaggioni, 1995) 
A3AR 
 
Gi 1, 2, 3  cAMP 
 Ca2+ Channels 
 PLD 
(Zhou et al., 1992) 
(Fossetta et al., 2003) 
(Mozzicato et al., 2004) 
Gq  PLC (Gessi et al., 2004). 
* Golf in striatum (Kull et al., 2000) 
 
 
: 	 	  	
" :	 ;A:= 
  	

 	 	 


 
 

  (, 	  /  /  	 
	?'+'.	
"< 
?C*	;9"&<())4=&%
	A^	
"
"

;%&<*882=
	A,	
"
 

 C|'% ;:  ^< ())*` ~
  &< ())4=& :< 



 
?'^  A,    
   	
	 
 

	

&
: 	
"
   
  	?' 
  .( %
;%9''.(= 
    
 ( 	 "
 
	  	?'
	


'^&%9''.(
<

	
     
  
<     

		
;6
&<())(=<
"
9

&

 
   
"" -	 
 

 ;9^= 
 
 

& (   
 
	
	
	


 9^ 	
"
 ;^
  &< ()).=`  	
" 	 AC

 
	
  	 	  9^ 	

	 


 ;~  &<
())0=& %
 
 "
	<     9^  9 	
"



&
10
,
	
		
"
		C
(9<
	
"  
	 
 		
/


	
 ;,&<()).`?
>"
	&<())4`1&<
())4=<  -  	

 _
 "
  /9^(  	

;^&<())4=&	
"

	"



	/
	
"

	""



	
	

";6
<())5=&
:
	-




		

	
  	 9 < 
	
 
  
 

;"
=	&+

<	

  9

	 
	   
"" 	

";6
&<())8=&
11
	 						
	

	
 	
	  	 

 9 	
" 
 	  ;	 "
  	< ())8= 

   
 	 	
 
"" 
 

	
 
	@


 

 

&  
 <   "  9 
 




-			


 



}

  
 	  
& +
<
 "
 

  
  	
" 9 	
"
 
 










 -
 
 ` "<    
 
 "


	

"
&:


<<




	



<
 -  
  9 
 
 "
 
	
&  
		< 
 
		&|
<-		
@

	
"

  	

  
 	   " 

 	
 ;	 .  0=& |  <  
"
 
		



-
 


;	4
 5=< 
 	 2 "
  
   	 
 



"
	

		&

: 
   
   
  


	
  		

 
	 
 
   	
"
   9 
 
	
		&		
@








		<
	



 
 

& + 
	-<	

	

  
"
  (9 

  
 


& ,
	
	 "	 
   *2  " 
"
   	  

	  	   & :
	
     	
   
  

    	 &:	

	 
 	  	
 

""  
 	
    
 	
 
  	  

" 
& :      	
" 	
 ; 	
= 


		
	

&-<	

	

	


<-
	
	
	
   
  -
  	
 <  

		

	 -
 
& +  	-  	
	 	<
12
	

	 
 ;
    	
	=  
			

		-

"	

	
   	  
"

< 
"
 	  

	
}	
&, 
 		<
 		
"

  	

 	 
	  	
"9 	
"
 	


   	



@-
	 	


&
C . 	
  

   
"  

 
 

	


<
	-

"&:	

	

	-
	&1	

	
	
	 	< 9A 

< " 	

  

	
  	%A<



 
	-
	


& +<
-


	
	


	

	
<
	



>	<

		



	;-
}	
	
	=&/

	

 
  
 "    "   	 


	;&&<
	
<	

<

  "
	=  
 
  

	 	-<  


-
 
  
& +  
< 

 /	
 
	
; / !*((  (&) 
	< 
-=  < 
	

	
05@)))	
	"


 & +  
  "  

   <

	

@/1
/;
<'<C<!1=<:-


;/<,<1
=?	;//<1&<?+<!1=&%

 
	

  	   <    
"" 





	
<	

  <  

  	 	 ;	
=   
	< 

		
 		

 ;
&&




=& +

<


	 	
 






		
 



	-

& C .   	
" -   	
	

 
	

	 	      "  
 

 	
 	
 ;9:'C9=   	
& :	
 

	   
 	  	<   	  } <
 	
  -
 
 
	    
	& + 	
  -   	

	 	  
 
-
	
	 	 ;-
	
	=  
 
	 
 
 	 


       	   



	
9;

	=&
13
+ 	 0  

 	

	 
    	
"
9 	

	 	

  
  	&? 	
	





	
&
,	  
 
	 	
   "
 
	  	
	
"
 
  
 	
	
	



	
	
;1&<
())8=<	"@


<

 
< 	  " 	 
  
@& ?	

"

"

<
	
		

<

	
		
"
<C|'%;,

&<()).=&<
	
?C*<
	-9(<(,.<

	   

   


  
 
 	 
 


  	

 	 ;A
  &< *880=& , 
<?C* 	
"      
 "
   	
	 	
  
 

& +
< 
 	 
 	 



 +	< 	9+<      +	
 	 "   
    	   	

;
&<()))`^/&<()).=&:


 
"
 (9 

  
 
 
&
:<	


?C*	

	
" 9 
 ;
 =  	  	 


	
"(9	
"
 ;(9
= 
(9 
  ;
    (9 
=& 
" 	

  	 
 	

 	  
 " 
	-

 	 . 	
&
: 
 	

 	
 -
    
	
 /
	 C #
	 ;/C#=< !
"
  #
	+	< 
"   
	
  	

 	
" A90(  A90.  

 AC&:  	
9:'C9 
   
 "& <   	

   
 	
	 



  

 
  
  "


9	
"
		0(.<
(9




-
&

+  	   
   	   
"

  
  

9

"

	
&C2
"
9 

   	 	 "< 

9 

	
	 		

	 "   
 
 
& + 

	
<  
  
 
	 9 	 
  " 
	

	
  < 
	
 -
< 
	

 
><


< < 	
	  CA1 
& 1	
 
   

	
14
	



	&+	45

   
 
 
 	 
 	
 ;9|= 

 
 
"
& 
 9| ;"
   C|'%= 
  	

         < 
	
 	
	
 
 

< "
 
 	
  	
 

"& : "	  9| 	   
  2)< 
  
	

	  " 
 	& ,   
  9 
 

	
	 
 
<    9 	 "   "
	
	  
 
 
& : " 
 
< ( 	
	&

< 
 	4	" " 
 

	& 1  
    
 
 9|  


"

C

	!
"
#
	&!
 		
  
< 
 		
    
	

	 	  
 	
 
  C  C

	
'	< !
"
  '
 1	  ?
	
& : 
	
	
			

	,6

	

	 
 

	
"  
 

< 	  "
 
 

< 	
	
<	
<	
 	
    	  		  ;  
	
	

	

		=&
:

		<-


	9



 
 
& :  
 	 5  (
 
& 
< 
-
  09  
,6 	 


" 

	
	
;9:'C9=	


		;',?C=<	<	-<	
<<<>><
		< 
<  <   
 & ,  



< 	


	
"
,6	 9

 
 "& ,	        9 



    
  	  	
 (9<  	 
-
"9
&!"<,6		

 
  	
" 9 
 ;
 =<  	
" (9

	


(9

&1
	"
+64











<	
	




&"


	
"
  <  


 


	 	 
 +64 -
 ;9A=

	  	
" 9 	
"
& +
< +64 
 	 
 
	  		
 	
 (9< 

  
 	

 
,6	 


	




&
15
 	 !"	
				"#	
#
			"				

%
9*<61*<
	'(<6,
	,(</.<A
*
	
*+

'	:-
	<
	<!
"

#
	<1
	
(6
@9
C

;6,9C=<
	A


A<		
.//<,<1


4 0/ &*2;*=3*4*5.;())7=
	
	
"				
C
	-
`
`	
	
	

 
16
Global gene expression proﬁles induced
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Abstract
The nutritional intake of phytoestrogens seems to reduce the risk of breast cancer or other neoplastic
diseases. However, these epidemiological ﬁndings remain controversial because low doses of
phytoestrogens, achievable through soy-rich diets, stimulate the proliferation of estrogen-sensitive
tumor cells. The question of whether such phytochemicals prevent cancer or rather pose additional
health hazards prompted us to examine global gene expression programs induced by a typical soy
product. After extraction from soymilk, phytoestrogens were deconjugated and processed through
reverse- andnormal-phasecartridges. The resultingmixturewasused to treat human target cells that
represent a commonmodel system for mammary tumorigenesis. Analysis of mRNA on high-density
microarrays revealed that soy phytoestrogens induce a genomic ﬁngerprint that is indistinguishable
from the transcriptional effects of the endogenous hormone 17b-estradiol. Highly congruent
responses were also observed by comparing the physiologic estradiol with daidzein, coumestrol,
enterolactone, or resveratrol, each representing distinct phytoestrogen structures. More diverging
transcriptional proﬁles were generated when an inducible promoter was used to reconstitute the
expression of estrogen receptor b (ERb). Therefore, phytoestrogens appear to mitigate estrogenic
signaling in the presence of both ER subtypes but, in late-stage cancer cells lacking ERb, these
phytochemicals contribute to a tumor-promoting transcriptional signature.
Endocrine-Related Cancer (2008) 15 161–173
Introduction
Epidemiological studies have linked an increased risk
of developing mammary or endometrial malignancies
to prolonged estrogen exposure due to early menarche,
oral contraceptives, nulliparity, late ﬁrst-term preg-
nancy, delayed menopause, or an estrogen replacement
therapy (McPherson et al. 2000, Clemons & Gross
2001, Nelson et al. 2002). In contrast, the dietary
intake of soy isoﬂavones such as genistein and daidzein
correlates with a lower incidence of breast and prostate
cancers (Ingram et al. 1997, Branca & Lorenzetti
2005). However, why endogenous estrogen hormones
or synthetic xenoestrogens increase cancer risk,
whereas natural phytoestrogens appear to exert an
opposite preventive action, is not understood.
In the normal resting mammary gland, estrogen
receptors (ERs) are expressed in only a small proportion
of epithelial cells that are largely non-dividing (Ali &
Coombes 2002). In contrast, enhanced expression of ERs
is a critical event in the pathogenesis of a majority
(w70%) of breast cancers and, accordingly, the growth
of malignant mammary tumors is estrogen dependent in
most cases (Hayashi et al. 1997, Gruvberger et al. 2001,
Rice & Whitehead 2006). Like other ER agonists,
phytoestrogens stimulate the proliferation of estrogen-
sensitive tumor cells in various experimental systems
(Hsie et al. 1998, Allred et al. 2001), and this growth-
promoting activity has raised concerns that soy products,
or similar phytochemicals, may represent an additional
health hazard for vulnerable risk groups (Messina et al.
2006). More skepticism regarding the true beneﬁts of
Endocrine-Related Cancer (2008) 15 161–173
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phytoestrogens came from the observation that hyper-
plasia of the epithelium and other markers of cell
proliferation are detectable in breast biopsies of pre- and
postmenopausal women after a period of dietary soy
supplementation (Petrakis et al. 1996, McMichael-Phil-
lips et al. 1998, Hargreaves et al. 1999). Thus,
establishing the consequences of soy intake in popu-
lations at high risk for breast or prostate cancer is an
important public health issue (Messina et al. 2006).
The present study was instigated by the notion that
essentially all cellular responses to estrogenic stimuli
culminate in transcriptional regulation, even though
some of the known effects are considered indirect or
non-genomic (Duan et al. 2001, McDonnell & Norris
2002, Levin 2003). Thus, oligonucleotide-based
microarrays, which are able to detect global expression
proﬁles at the transcriptional level, provide a con-
venient molecular approach to analyze biological
endpoints of phytoestrogen exposure. Particular atten-
tion has been given to the question of whether the
native hormone 17b-estradiol and phytoestrogens
induce similar or different transactivation functions.
For example, a gene expression survey performed on
immature mice treated with genistein or 17b-estradiol
yielded identical transcriptional responses in the uterus
(Moggs et al. 2004). Other reports concluded that there
are signiﬁcant differences between the transcriptional
proﬁles elicited by genistein or other estrogenic
compounds in the reproductive tract of female rats
(Naciff et al. 2002, Hong et al. 2006). Additional
analyses were carried out under more tightly controlled
cell culture conditions. One of these studies concluded
that there is a partial overlap between the expression
patterns elicited by 17b-estradiol and phytoestrogens,
including genistein, daidzein, and coumestrol, in
human MCF7 breast cancer cells (Ise et al. 2005).
Another contrasting study with MCF7 cells yielded no
substantial relationship between the transcriptional
effects of genistein and the endogenous hormone
17b-estradiol (Wang et al. 2004).
These conﬂicting results prompted us to examine
genome-wide expression proﬁles in human MCF7 and
T47D breast cancer cells exposed to either single
phytoestrogens or the natural phytoestrogen mixture
extracted from a representative soy product. Soymilk
has been selected for this study because it represents a
widespread nutritional supplement and it is increasingly
used as a basic component of food products for
newborns. As a reference control, an analogous extract
from cow milk has been included in view of its much
lower phytoestrogen content. The comparison of
expression data comprising 47 400 human transcripts
revealed that the particular ﬁngerprint induced by
soymilk phytoestrogens coincides with the known
transcriptional response of breast cancer cells to the
endogenous 17b-estradiol hormone. In addition, we
found that soy phytoestrogens induce nearly identical
expression ﬁngerprints as other structurally distinct
phytoestrogens from different sources. A phytoestrogen
signature that deviates from the characteristic transcrip-
tional ﬁngerprint of 17b-estradiol was observed when
an inducible genetic construct was used to express, in
addition to ERa, also the ERb subtype.
Materials and methods
Chemicals
Daidzein and resveratrol were purchased from Sigma–
Aldrich; 17b-estradiol, coumestrol, and enterolactone
were from Fluka (Buchs, Switzerland). The inhibitor
ICI 182 780 was purchased from TOCRIS Bioscience
(Avonmouth, UK). All solvents and reagents were of
analytical grade quality.
Extraction and analysis of milk samples
The sample preparation procedure developed for
extracting phytoestrogens from milk, including the
removal of endogenous estrogen hormones, is fully
described elsewhere (Antignac et al. manuscript in
preparation). Brieﬂy, the samples (cow milk or soymilk
obtained from a local retailer) were extracted in 10 ml
aliquots with acetate buffer (2 M, pH 5.2) and acetone.
After centrifugation, the supernatants were collected
and the acetone phase was evaporated under a nitrogen
stream. Subsequently, an enzymatic hydrolysis was
carried out by overnight incubation (52 8C) with a
puriﬁed Helix pomatia preparation (Sigma). This
deconjugation step was followed by puriﬁcation
through two successive cartridges combining a reverse
(C18) and a normal (silica) stationary phase (SDS,
Peypin, France). After evaporation of the methanol
eluates, the remaining residues were reconstituted in
30 ml dimethyl sulfoxide (DMSO) for cell culture
experiments. Separate cow milk and soymilk samples
were subjected to the same procedure, except that a
deuterated compound (daidzein-d3) was included as
internal standard. These samples were analyzed by
liquid chromatography–tandem mass spectrometry for
the quantitative determination of phytoestrogens
(Antignac et al. 2003). The 17b-estradiol measure-
ments were performed according to a previously
described method (Courant et al. 2007).
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Cell culture and treatments
Human T47D.Luc cells (BioDetection Systems,
Amsterdam, The Netherlands) were maintained in a
1:1 mixture of Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM) and Ham’s F12 medium supplemented with
sodium bicarbonate, 1 mM L-glutamine, and 7.5% fetal
bovine serum (FBS; Invitrogen). The T47Db deriva-
tives (Stro¨m et al. 2004) were grown in the presence of
1 mg/ml tetracycline. This antibiotic was removed for a
period of 48 h to induce the expression of ERb. The
MCF7 cell line subtype BUS (Soto et al. 1995) was
maintained in DMEM supplemented with 10% FBS.
The other antibiotics used were 0.1 U/ml penicillin and
0.1 mg/ml streptomycin (Invitrogen). All cell lines
were cultured at 37 8C in xenoestrogen-free plastic
(Corning Inc., Grand Island, New York, USA) under
humidiﬁed air containing 5% CO2. Before each
experiment, the cells were transferred to phenol red-
free medium and cultured for 48 h in the presence of
5% dextran/charcoal-stripped FBS (DCC-FBS).
DMSO stocks of each test compound were added to
the culture medium. Unless otherwise indicated, the
ﬁnal solvent concentration was adjusted to 0.1% (v/v).
Cytotoxicity assays
A commercial kit was used to measure intracellular
ATP levels. Brieﬂy, MCF7 cells were grown in multi-
well plates as outlined before and exposed to the
indicated fractions of soymilk or cow milk extracts.
After 24 h, the CellTiter-Glo reagent (Promega) was
added and the luminescent signal was recorded in a
microplate reader following the manufacturer’s
instructions. Additionally, the CellTiter 96 and
CytoTox 96 assays (Promega) were used to monitor
the overall metabolic activity and the release of lactate
dehydrogenase.
ER-CALUX assay
The ER-mediated chemical-activated luciferase
expression (ER-CALUX) assay was carried out
following the instructions provided by BioDetection
Systems. Brieﬂy, T47D.Luc cells were seeded in
microtiter plates at a density of 5000 cells per well in
0.1 ml phenol red-free medium containing 5% DCC-
FBS. After 24 h, the medium was renewed and the cells
were incubated for another 24 h followed by the
addition of the indicated test compounds dissolved in
DMSO. Solvent controls and a standard 17b-estradiol
dose response were included on each plate. After 24 h
exposure times, cells were harvested, lysed, and
assayed for luciferase activity on a Dynex microplate
luminometer (Legler et al. 1999).
Microarray hybridization, data acquisition,
and analysis
After a 24 h treatment with test compounds, cells were
collected by trypsinization and total RNA was
extracted using the RNeasy kit (Qiagen). Amount and
quality of the RNA fractions were evaluated by u.v.
spectrophotometry (260 and 280 nm wavelength)
followed by examination of the probes by capillary
electrophoresis on Agilent Bioanalyzers. The Gene-
Chip expression and IVT (in vitro transcription)
labeling kits (Affymetrix) were used for the synthesis
of cDNA and complementary RNA respectively. The
biotin-labeled RNA was fragmented and hybridized on
human genome U133 plus 2.0 microarrays (Affyme-
trix, Santa Clara, CA, USA) following the manufac-
turer’s instructions. After hybridization (16 h), the
microarrays were processed by automated washing on
the Affymetrix Fluidics Station 400. Staining of the
hybridized probes was performed with ﬂuorescent
streptavidin–phycoerythrin conjugates (1 mg/ml; Invi-
trogen). The scanning of DNA microarrays was carried
out on an Affymetrix laser instrument. Microarray
quality assessment, condensing of the probe sets, data
normalization, and ﬁltering were conducted using the
Expressionist software (Genedata AG, Basel, Switzer-
land). The t-tests were performed between controls and
treated cells to assess the statistical signiﬁcance of
differentially expressed genes. False discovery rates
were determined according to the Benjamini–Hoch-
berg method (Benjamini & Hochberg 1995). Finally,
the means of three to ﬁve replicates were imported into
a Microsoft Excel ﬁle for graphical representation and
determination of correlation coefﬁcients. The ‘Gene
Ontology’ database (www.geneontology.org) was
consulted for the molecular function of each transcript
and, for simplicity, only gene products with a known or
inferred function are displayed in the ﬁgures.
Real-time RT-PCR
PCR quantiﬁcations were carried out to validate the
microarray hybridization results. Primers for the selected
transcripts were obtained from Applied Biosystems
(Foster City, CA, USA). Brieﬂy, 100 ng cDNA were
mixedwith 100 nMforward and reverse primers in aﬁnal
volumeof 25 ml. The reactionswere performed in anABI
PRISM 7700 Sequence Detection System (Applied
Biosystems) for 45 cycles (95 8C for 15 s, 60 8C for
1 min) after an initial 10-min incubation at 95 8C.
The fold change in the expression of each gene was
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calculatedusing the 2KDDCT method (Livak&Schmittgen
2001), with the abundant glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) transcript as an endogenous
control.
Results
Sample preparation and analysis
After liquid extraction and enzymatic deconjugation,
the soymilk and cow milk samples were subjected to a
two-step fractionation procedure using reverse-phase
(C18) and normal-phase (SiOH) cartridges. The
quantitative analysis by liquid chromatography
coupled to tandem mass spectrometry conﬁrmed that
soymilk contains large quantities of the isoﬂavones
genistein and daidzein, whereas cow milk is charac-
terized by the presence of low levels of enterolactone
together with trace amounts of other phytoestrogens
(Table 1). An additional determination by gas
chromatography–mass spectrometry was used to
verify that endogenous estrogen hormones, including
17b-estradiol, were removed from the cowmilk sample
during the ﬁnal solid-phase extraction step (data not
shown). For the subsequence cell culture experiments,
each isolate from a 10 ml sample was reconstituted in
30 ml DMSO, which proved to be compatible with
the solubility properties of the various phytoestrogens.
Dose-dependent transactivation from a minimal
estrogen-responsive promoter
Initially, human MCF7 and T47D breast cancer cells
were exposed to increasing concentrations of the
soymilk and cow milk extracts. Cell viability was
tested 24 h later by measuring the intracellular ATP
pool, which is used as an indicator of metabolic
activity. The resulting dose responses demonstrated
that no cytotoxic reactions were triggered when the cell
culture medium contained up to 0.5% (v/v) milk
extracts dissolved in DMSO. This lack of cytotoxicity
was conﬁrmed when the metabolic activity was
assessed by measuring the capacity to reduce a
tetrazolium reagent or when the cell integrity was
measured by monitoring the release of lactate
dehydrogenase (data not shown).
Next, the soymilk and cow milk extracts were tested
for their overall estrogenic activity using a standard
reporter gene assay. For that purpose, we exploited a
stably transfected carcinoma cell line (T47D.Luc) that
carries a chromosomally integrated reporter gene
sequence (Legler et al. 1999). In this genetically
modiﬁed cell line, the ﬁreﬂy (Photinus) luciferase gene
is under transcriptional control of a minimal promoter
displaying tandem repeats of estrogen response
elements (5 0-GGTCACTGTGACC-3 0). This artiﬁcial
construct drives the expression of ﬁreﬂy luciferase in
response to ER activation. Thus, to monitor estrogenic
activity, cell lysates were examined for luciferase
activity after a 24 h treatment with progressively
increasing concentrations of 17b-estradiol or the
different extracts added to the cell culture medium.
In all these treatments, the ﬁnal concentration of the
DMSO solvent was 0.1% (v/v).
In a series of control reactions, the synthetic
promoter mediated a dose-dependent luciferase
induction in response to the 17b-estradiol standard.
This expected estrogenic effect reached peak levels at a
hormone concentration of 60 pM (Fig. 1). A similar
level of reporter gene induction was observed in the
cells incubated with soymilk extract. In agreement with
its limited phytoestrogen content, however, the
corresponding cow milk isolate resulted in only
minor reporter gene induction when compared with
the soy product (Fig. 1). These responses to the
treatment with 17b-estradiol or soymilk extract were
completely suppressed by the addition of the ER
antagonist ICI 182 780 at a concentration of 0.1 mM
(data not shown).
Global expression proﬁles elicited by natural
phytoestrogen mixtures
Previously, we found that the MCF7 breast cancer cell
line is markedly more responsive than T47D cells to
estrogenic stimuli, thus yielding a wider range of
estrogen-regulated genes as well as larger amplitudes
of expression changes (Buterin et al. 2006). As a
consequence, the MCF7 cells were used herein to
perform genome-wide analyses of endogenous
Table 1 Concentrations (ng/ml) determined for the target
phytoestrogens in the analyzed soymilk and cow milk samples
Concentration
Compound Soymilk Cow milk
Daidzein 1233 8.3
Genistein 5175 5.6
Equol nd 2.6
Formononetin 9.6 1.8
Biochanin A nd nd
Glycitein 98.5 nd
Enterolactone 1.1 5.2
Matairesinol nd nd
Coumestrol nd nd
Resveratrol nd nd
nd, not detected at the limit of detection, which varied from 0.05
to 0.7 ng/ml depending on the compound.
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transcripts after a treatment with phytoestrogen
mixtures reconstituted in culture medium. The target
cells were incubated in triplicates with soymilk or cow
milk extracts to reach a ﬁnal solvent concentration of
0.1% (v/v). After 24 h exposures, a fraction of RNA
from each sample was analyzed using Affymetrix
microarrays that display the sequences of 47 400
human transcripts. To identify genes that are suscep-
tible to ER regulation, these microarray data were
normalized and subjected to statistical analysis. Also,
in view of the large number of regulated genes, the
expression data were subjected to a ﬁlter for transcripts
that exhibited at least a ﬁvefold change relative to the
solvent control, thereby eliminating the vast majority
of gene products that are more moderately affected or
not altered at all following the phytoestrogen treat-
ment. The signiﬁcance threshold was P!0.01,
yielding false discovery rates in the range of 0.02–0.1
(Benjamini & Hochberg 1995). According to these
criteria, a total of 358 different transcripts were up- or
down-regulated by more than ﬁvefold in response to
incubation with the soymilk extract. In contrast, the
gene expression proﬁle induced by the cow milk
sample deviated only marginally from the background
transcriptional pattern observed in the solvent control
group. In this case, only six transcripts were affected by
more than ﬁvefold changes, thus reﬂecting the much
lower phytoestrogen concentration in cow milk.
Figure 2A shows the transcripts displaying the
highest amplitude of regulation in response to the
treatment with soymilk phytoestrogens. The majority
of these transcripts encode for proteins involved in
DNA metabolism (ribonucleotide reductase M2
(RRM2), thymidylate synthetase, thymidine kinase 1;
see legend to Fig. 2 for abbreviations), DNA
replication or recombination (minichromosome
maintenance-deﬁcient 10, CDT1, topoisomerase II-a
(TOP2A), primase 1, RAD51), cell division cycle
(cyclin A2, cell division cycle 2 (CDC2), CDC6,
TTK), chromosome segregation and centromere func-
tion (aurora kinase B, kinesin-like 7 (KNSL7), Spc24,
Spc25, cell division cycle associated 1, kinetochore
associated 2, kinesin family member 2C,
extra-spindle poles like 1, abnormal spindle-like
microcephaly), or inhibition of apoptosis (baculoviral
IAP repeat-containing 5). Together with the over-
expressed proto-oncogenes myeloblastosis oncogene-
like 1 (MYBL1) and MYBL2 as well as two different
proliferation markers (antigen identiﬁed by mono-
clonal antibody Ki-67 and Opa-interacting protein 5),
this transcriptional proﬁle reﬂects the typical mitotic
signature observed in estrogen-stimulated breast
cancer cells (Lobenhofer et al. 2002, Coser et al.
2003, Frasor et al. 2003, Vendrell et al. 2004, Buterin
et al. 2006, Lavigne et al. 2007).
A side-by-side comparison indicated that the
observed expression changes resulting from exposure
to the soy phytoestrogens are similar to the
transcriptional effects of the endogenous hormone
17b-estradiol. In fact, all transcripts that were
increased by incubation with the soymilk extract
were also up-regulated following the treatment with
17b-estradiol (Fig. 2A). To analyze this presumed
relationship in more quantitative terms, the mRNA
proﬁle induced by the soymilk extract was plotted
against the corresponding values obtained with 17b-
estradiol. All transcripts were included in this analysis
that showed at least a ﬁvefold up- or down-regulation
in the phytoestrogen treatment group. The threshold
for statistical signiﬁcance was P!0.01. Figure 2B
shows that the data points in this comparison grouped
in two distinct clusters reﬂecting those genes that were
over-expressed and those that were under-expressed
relative to the solvent control. A linear regression
analysis of all 358 pairs of data yielded an overall
correlation coefﬁcient of RZ0.87, thereby exceeding
the values (Rz0.6) found in another similar study that
Figure 1 Luciferase reporter gene assay. Stably transfected
T47D.luc cells were incubated with 17b-estradiol (E2 at
concentrations of 1–100 pM) as well as soymilk or cow milk
extracts. The ﬁnal concentration of the DMSO solvent was 0.1%
(v/v). ER activation was determined by measuring the luciferase
induction from a minimal promoter containing repeats of
estrogen response elements (mean values of ﬁve to six
independent experiments). The results are shown in percen-
tage of the induction observed with 60 pM 17b-estradiol.
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compared soy extracts with 17b-estradiol (Ise et al.
2005). The close correspondence of expression values,
demonstrated in Fig. 2B, lends support to the notion
that soy phytoestrogens and 17b-estradiol induce
nearly identical transcriptional responses in MCF7
cells. Thus, in contrast to previous reports (Wang
et al. 2004, Ise et al. 2005), we found that the
transcriptional machinery of this breast cancer cell
line responds in a very monotonous manner to distinct
estrogenic stimuli.
Figure 2 Comparison of genome-wide transcriptional changes in MCF7 cells exposed to milk extracts or 17b-estradiol.
(A) Transcripts with the highest amplitude of induction following a treatment with soymilk extract. The level of the same transcripts
has also been determined for the treatment with 17b-estradiol (30 pM) or an analogous cowmilk extract. The extracts were dissolved
in DMSO and added to the cell culture medium to a ﬁnal solvent concentration of 0.1%. In each case, the fold changes were
calculated against the corresponding values obtained in control experiments with solvent alone (mean values of three independent
experiments). (B) Linear regression analysis of pairs of data obtained from the experiments with soymilk extract and 17b-estradiol
(30 pM). A ﬁvefold change (up- or down-regulation) in the soymilk-treated samples relative to the controls was used as the cut-off to
ﬁlter the data. A total of 358 transcripts passed the statistical threshold of P!0.01. RRM2, ribonucleotide reductase M2; AURKB,
aurora kinase B; MCM10, minichromosome maintenance-deﬁcient 10; TYMS, thymidylate synthetase; CCNA2, cyclin A2; KNSL7,
kinesin-like 7; Spc25, kinetochore protein Spc25; UHRF1, ubiquitin-like, containing PHD and RING ﬁnger domains 1; TK1, thymidine
kinase 1; FOXM1, forkhead box 1; GAJ, GAJ protein; MYBL1, myeloblastosis oncogene-like 1; MYBL2, myeloblastosis oncogene-
like 2; TOPK, T-LAK cell-originated protein kinase; FKSG14, leucine zipper protein FKSG14; KNTC2, kinetochore associated 2;
CDC2, cell division cycle 2; CDT1, chromatin licensing and DNA replication factor 1; TOP2A, topoisomerase II-a; CDC6, cell division
cycle 6; KLIP1, KSHV latent nuclear antigen interacting protein 1; TMPRSS3, transmembrane protease serine 3; MKI67, antigen
identiﬁed by monoclonal antibody Ki-67; DLG7, discs large homolog 7; Spc24, kinetochore protein Spc24; OIP5, Opa-interacting
protein 5; NUSAP1, nucleolar and spindle associated protein 1; CDCA1, cell division cycle associated 1; BIRC5, baculoviral IAP
repeat-containing 5; ANLN, anilin; BRRN1, barren homolog; PRO2000, PRO2000 protein; KIF2C, kinesin family member 2C;
PRIM1, primase 1; ESPL1, extra-spindle poles like 1; ASPM, abnormal spindle-like microcephaly; TTK, TTK protein kinase; RAD51,
radiation sensitive 51; TCF19, transcription factor 19; SHCBP1, ortholog of mouse Shc SH2-domain binding protein 1.
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Validation using real-time PCR
Real-time reverse transcriptase-PCR (RT-PCR) assays
were carried out on representative sequences to
conﬁrm the tight correlation between the expression
proﬁles induced by soy phytoestrogens and 17b-
estradiol. The following transcripts were tested:
RRM2 polypeptide, CDC2, TTK (a protein kinase),
and UDP-N-acetylglucosaminyltransferase 5. The
exposure with soy phytoestrogens was performed
with three different proportions of extract in the cell
culture medium between 0.001 and 0.1% (v/v). In view
of the phytoestrogen contents listed in Table 1, these
residue levels translate to genistein concentrations
ranging from 0.1 to 10 mM. Incubations with the 17b-
estradiol reference were performed using the standard
concentration of 30 pM. After normalization with the
constitutive GAPDH transcript, expression values are
indicated as the ratio between treated cells and solvent
controls. A linear regression analysis of the resulting
RT-PCR values yielded correlation coefﬁcients of
RZ0.92–0.98, thus conﬁrming that phytoestrogens
and the physiologic estradiol hormone induce very
similar transcriptional responses (Fig. 3).
Expression patterns induced by single
phytoestrogens
We already demonstrated that the most abundant soy
phytoestrogen, i.e., genistein, induces global gene
expression proﬁles in both MCF7 and T47D cells
that are indistinguishable from the transcriptional
changes resulting from 17b-estradiol treatments
(Buterin et al. 2006). A similar convergence was now
obtained when we assessed the response of MCF7 cells
to another major soy phytoestrogen, i.e., daidzein
tested at a concentration of 1 mM (Fig. 4A). Sub-
sequently, this study was extended to different
categories of phytoestrogens including coumestrol
(found in white clover), resveratrol (found in grape
skins and red wine), and enterolactone (an endogenous
metabolite generated from plant lignans). The criteria
for inclusion of the transcripts into the correlation
analyses of Fig. 4 were again a fold change O5 and a
corresponding P value !0.01. Compared with the
daidzein treatment, the number of signiﬁcantly
regulated transcripts was slightly higher in the
coumestrol experiment (Fig. 4B) and markedly
reduced in the resveratrol and enterolactone treatments
(Fig. 4C and D). However, a direct comparison with
the effects of 17b-estradiol on the same human genes
yielded correlation coefﬁcients of RZ0.85–0.92,
further supporting the idea that, at least in a low-dose
range, all kinds of phytoestrogens generate expression
proﬁles in human breast cancer cells that are super-
imposable with the transcriptional pattern elicited by a
17b-estradiol stimulus.
Modulation of expression ﬁngerprints by ERb
RT-PCR quantiﬁcations with oligonucleotide primers
speciﬁc for each ER subtype showed that the
predominant mRNA in MCF7 and T47D cells is the
one coding for ERa, whereas ERb transcripts remained
undetectable (data not shown). These ﬁndings are
consistent with previous studies reporting the presence
of only trace amounts of ERb transcripts in T47D and
essentially no such transcripts in MCF7 cells (Legler
et al. 1999, Lobenhofer et al. 2002). By immuno-
blotting methods, it has also been shown that there is
no detectable ERb protein in T47D cells (Stro¨m et al.
2004). The lack of an appropriate breast cancer cell
line containing signiﬁcant amounts of ERb protein can
be circumvented by taking advantage of a genetic
system (T47Db) in which a tetracycline-regulated
construct drives the expression of a full-length
human ERb sequence (Stro¨m et al. 2004). Here,
these stably transfected T47Db derivatives have
been used to examine the contribution of ERb to
the transcriptional reprogramming triggered by
phytoestrogens.
T47Db cells were exposed to coumestrol (at a
concentration of 1 mM) because this particular phyto-
chemical displays the highest afﬁnity for ERb among
Figure 3 RT-PCR analysis of selected transcripts that were
regulated following exposure of MCF7 cells to estrogenic
stimuli. The results obtained with three different concentrations
of the soymilk extract (0.001–0.1%; v/v) were plotted against
the corresponding values obtained in the experiment with 17b-
estradiol (30 pM). The fold changes were measured using the
GAPDH transcript as an endogenous control (mean values of
four to ﬁve independent determinations). The linear regression
analysis to determine the degree of similarity between the
transcriptional changes induced by soymilk extract and
17b-estradiol yielded correlation coefﬁcients of RZ0.92–0.98.
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all phytoestrogens tested to date (Kuiper et al. 1997,
1998, Bovee et al. 2004). The transcriptional changes
were tested in the presence of tetracycline, i.e., under
conditions that suppress the expression of ERb, as well
as after tetracycline withdrawal, resulting in promoter
activation and ERb expression. In the absence of
tetracycline, the level of mRNA coding for ERb is four
to ﬁve times higher than the corresponding ERa
transcripts, thus leading to substantial quantities of
both receptor subtypes (Stro¨m et al. 2004). To
eliminate possible confounding effects due to the
antibiotic used for induction, the ﬁngerprints obtained
in the presence of tetracycline were analyzed against
appropriate solvent controls containing the same level
of antibiotic. Conversely, the ﬁngerprints obtained
after tetracycline withdrawal, promoting ERb
expression, were determined against corresponding
controls without tetracycline in the medium.
Figure 5 illustrates the distinctly different transcrip-
tional proﬁles induced by coumestrol in the absence or
in the presence of ERb. To simplify the representation
of data, the graph of Fig. 5 shows only those transcripts
that were up-regulated by a fold change O10 in at
least one of the treatment groups (P!0.01 for all
transcripts). The response obtained in T47Db cells
containing ERa alone involves, for example, an
overexpression of interleukin 20 (IL 20), chemokine
ligand 12 (CXCL2), insulin-like growth factor-binding
protein-4 (IGFBP4), MYB or trefoil factor 1 (TFF 1
also known as pS2). The range of regulated target
genes did not change when, in the absence of
tetracycline, both ERa and ERb were expressed in
the same cell line. However, the induction of many
transcripts was attenuated in the presence of ERb
(Fig. 5), indicating that this additional receptor subtype
is able to partially suppress some transactivation
functions mediated by ERa. Conversely, in the
presence of ERb, other transcripts were regulated
with larger amplitudes of induction than in the cells
expressing only ERa. This second category of genes,
Figure 4 (A to D) Comparison between 17b-estradiol and single phytoestrogens daidzein (A), coumestrol (B), resveratrol (C), and
enterolactone (D). MCF7 cells were incubated with the indicated phytochemicals at the concentration of 1 mM (three to four
independent replicates). The resulting expression changes were plotted against the corresponding data obtained with 17b-estradiol
(30 pM). A ﬁvefold change in the phytoestrogen-treated samples was used as the cut-off to ﬁlter the data, and the number of
signiﬁcantly (P!0.01) regulated transcripts is indicated for each compound. The quantitative relationship between the different
molecular ﬁngerprints was determined by linear regression analyses, yielding correlation coefﬁcients of RZ0.85–0.92.
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which become more responsive in the presence of ERb,
include, for example, tripin, TOP2A (see legend to
Fig. 5 for abbreviations), the cyclin-dependent kinase
inhibitors CDKN3 and CDKN2C as well as multiple
members of the kinesin family (KNSL7, KIF20A,
KIF14).
Toward a distinctive phytoestrogen signature
Many phytoestrogens display a selective binding to
ERb whereas 17b-estradiol has approximately the
same afﬁnity for both major ER subtypes (Kuiper et al.
1997, 1998). Thus, we explored the hypothesis that the
preferential interaction of these phytochemicals with
ERb may mediate a more distinctive transactivation
function. These experiments were again carried out
with coumestrol because of its superior afﬁnity for ERb
compared with other phytoestrogens (Bovee et al.
2004). The expression changes were subjected to a
ﬁlter for transcripts that exhibit at least a threefold
induction relative to untreated controls. A statistical
threshold of P!0.05 was applied to all differentially
expressed transcripts.
In T47Db cells containing only ERa, in the presence
of tetracycline, we observed the usual tight correlation
between the expression proﬁles generated by 17b-
estradiol and coumestrol, with 79 transcripts matching
the ﬁltering criteria (Fig. 6A). Upon linear regression
analysis, the correlation coefﬁcient between the
17b-estradiol and coumestrol data reached a value of
RZ0.90. For the same transcripts, however, this
correlation coefﬁcient was reduced to RZ0.70 when
the cells, in the absence of tetracycline, were able to
express the ERb subtype (Fig. 6B). Also, the slope of the
linear regression decreased substantially from 0.7
Figure 5 Impact of ERb on gene expression proﬁles in breast cancer cells. T47Db cells were exposed to coumestrol (1 mM) either in
the presence or in the absence of tetracycline. The fold changes of each transcript (mean values of three independent experiments)
were calculated using, as the reference, solvent controls with or without tetracycline. ERa gene expression proﬁle induced in cells
containing only ERa (in the presence of tetracycline). ERaCb gene expression proﬁle induced in cells containing both ERa and ERb
(in the absence of tetracycline). IL20, interleukin 20; PDLIM3, PDZ and LIM domain 3; DHRS2, dehydrogenase/reductase (SDR
family) member 2; CXCL12, chemokine ligand 12; FABP5, fatty acid binding protein 5; KCNK5, potassium channel, subfamily K,
member 5; IGFBP4, IGF binding protein 4; MYB, myeloblastosis oncogene; TMPRSS3, transmembrane protease serine 3; IRS1,
insulin receptor substrate 1; ST8SIA-VI, a-2,8-sialyltransferase; RASGRP1, RAS guanyl releasing protein 1; NPY1R, neuropeptide
Y receptor 1; RERG, RAS-like estrogen-regulated growth inhibitor; PIF1, DNA helicase homolog 1; BIN3, bridging integrator 3;
TFF1, trefoil factor 1; GAL, galanin; PLK1, polo-like kinase 1; TOSO, regulator of Fas-induced apoptosis; PDZK1, PDZ domain
containing 1; ASPM, abnormal spindle-like microcephaly; SLC26A2, solute carrier family 26 member 2; ADRA2A, adrenergic a-2A
receptor; STC2, stanniocalcin 2; MYC, myelocytomatosis oncogene; GPSM2, G-protein signaling modulator 2; CENPF, centromere
protein F; CDKN3, cyclin-dependent kinase inhibitor 3; IL17RB, interleukin 17 receptor B; ANLN, anilin; NUSAP1, nucleolar and
spindle associated protein 1; ANP32E, acidic nuclear phosphoprotein 32 family E; RACBAP1, Rac GTPase-activating protein 1;
STK6, serine–threonine kinase 6; KIF18A, kinesin family member 18A; MCLC, mid-1-related chloride channel 1; GTSE1, G2 and S
phase-expressed 1; HMGB2, high-mobility group box 2; CDKN2C, cyclin-dependent kinase inhibitor 2C; HCAP-G, chromosome
condensation protein G; TRAF4, TRAF4-associated factor 1; PKIB, protein kinase inhibitor-b; CTNNAL1, catenin a-like 1; CDCA3,
cell division cycle associated 3; MKI67, antigen identiﬁed by monoclonal antibody Ki-67; Spc25, kinetochore protein Spc25; CCNA2,
cyclin A2; TOP2A, topoisomerase II-a; NEK2, never in mitosis gene a-related kinase 2; PMSCL1, polymyositis–scleroderma
autoantigen 1; HMMR, hyaluronan-mediated motility receptor; FHL1, four-and-a-half LIM domains 1; KNSL7, kinesin-like 2; XTP1,
HBxAG transactivated protein 1; DEPDC1, DEP domain containing 1; KIF20A, kinesin family member 20A; KIF14, kinesin family
member 14; GREB1, GREB1 protein.
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(Fig. 6A) to 0.3 (Fig. 6B), reﬂecting a diminished
response to 17b-estradiol, relative to the effects of
coumestrol, in cells expressing ERb. Thus, the similarity
of transcriptomic patterns generated by 17b-estradiol and
coumestrol is less pronounced in the presence of ERb,
conﬁrming the notion that this particular receptor subtype
may mediate differential cellular responses when it is
stimulated by phytoestrogens.
Discussion
Breast cancer has become the most commonmalignancy
among American and European women (Rice &White-
head 2006) but, in eastern countries such as Japan, the
incidence of breast cancer is only about one-third that of
western populations. This difference has often been
attributed to a much higher dietary intake of soy
phytoestrogens (Konstantakopoulos et al. 2006, Marti-
nez et al. 2006, McCarty 2006, Messina et al. 2006).
However, despite the large amount of research conducted
in the last years, no clear consensus has emerged
regarding the preventive action of phytoestrogens against
cancer. There is still no conclusive evidence that the
ingestion of phytoestrogens is directly related to a
reduced incidence of breast cancer, or whether phytoes-
trogens rather represent a biomarker of generally healthy
diets (Martinez et al. 2006, Rice & Whitehead 2006).
At low physiologic serum concentrations that are
normally achieved by nutritional intake, phytoestro-
gens are likely to act through modulation of estrogen
signaling. In fact, these lower serum concentrations
appear insufﬁcient to inhibit tyrosine kinases or other
enzymes that may provide alternative targets of
phytoestrogen effects (McCarty 2006). Most estrogenic
responses are mediated by two members of the nuclear
steroid receptor superfamily, i.e., ERa and ERb. Both
receptors constitute ligand-stimulated transcription
factors that associate with co-regulatory partners to
remodel chromatin and recruit the general transcription
machinery to downstream genes (Katzenellenbogen &
Katzenellenbogen 2000, Hall et al. 2001, Moggs &
Orphanides 2001, Safe 2001). Although both receptors
bind to the same consensus estrogen-responsive
element within gene promoters, ERa and ERb have
been shown to exert partially antagonistic effects
(Omoto et al. 2003, Stro¨m et al. 2004).
Several ﬁndings converge on the idea that the
proliferative stimulus mediated by activation of ERa
can be opposed by the expression of ERb. First, the
knockout mice lacking ERb are more susceptible than
wild-type controls to develop markers of epithelial
hyperplasia in the mammary gland (Fo¨rster et al.
2002). Second, the mRNA coding for ERa is
up-regulated during cancer progression, whereas the
ERb transcript is reduced in part via promoter
methylation (Iwao et al. 2000, Rutherford et al. 2000,
Rody et al. 2005, Park et al. 2006). Third, the
continued expression of ERb in breast tumors is
associated with low aggressiveness and improved
survival rates compared with ERb-negative counter-
parts (Hopp et al. 2004). Fourth, the activation of ERa
promotes the growth of breast cancer cells both in
culture and in animal models (Soto et al. 1995, Hsie
et al. 1998, Allred et al. 2001, Ju et al. 2006) but, when
ERb is restored using an appropriate expression vector,
it exerts a negative effect on cell proliferation or even
induces apoptosis (Omoto et al. 2003, Skliris et al.
2003, Stro¨m et al. 2004). This antiproliferative action
of ERb correlates with the down-regulation of several
factors involved in DNA replication and the cell cycle
machinery (Lin et al. 2007).
Contrary to 17b-estradiol, which does not discrimi-
nate between ERa and ERb, phytoestrogens bind to
ERb with up to ﬁve times higher afﬁnities compared
with ERa (Kuiper et al. 1997, 1998). This ﬁnding
appears relevant in view of the possible action of ERb
as a tumor suppressor because phytoestrogens may be
able to trigger beneﬁcial responses through their
preferential interaction with the ERb subtype.
However, such a protective effect is abrogated in
cells that specialize on the expression of ERa with
minimal residual amounts of ERb. This possible
mechanism was supported when, in the present report,
we analyzed the transcriptional ﬁngerprints induced
by soymilk extracts in human breast cancer cells. This
type of soy product has been tested in the context of
Figure 6 Diverging expression proﬁles in the presence of ERb.
T47Db cells were challenged with 17b-estradiol (30 pM) or
coumestrol (1 mM), either in the presence or in the absence of
tetracycline. The fold changes of each transcript (mean values
of three independent experiments) have been calculated using,
as the reference, solvent controls with or without tetracycline.
(A) Comparison of gene expression proﬁle in cells containing
only ERa (in the presence of tetracycline). (B) Comparison of
expression proﬁles in cells containing both ERa and ERb (in the
absence of tetracycline). These graphs illustrate that ERb
decreases both the correlation coefﬁcient and the slope of the
linear regression.
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this study because of its high content in isoﬂavones
with estrogenic activity, such that the ﬁndings may be
extrapolated to a wide range of other soy-based foods
and supplements. Unlike previous reports (Wang et al.
2004, Ise et al. 2005), we observed that this natural
mixture of soy phytoestrogens, as well as other types
of phytoestrogens, induces a stereotyped expression
ﬁngerprint in breast cancer cells containing high
levels of ERa but essentially no ERb. Thus, in the
absence of ERb, all tested phytoestrogens result in
essentially the same expression changes as those
induced by the endogenous 17b-estradiol, and this
recurrent genomic proﬁle reﬂects the proliferative
response mediated through ERa activation. This
particular signature includes the up-regulation of
multiple factors involved in cell cycle, DNA
replication, chromosome segregation, and inhibition
of apoptosis. However, when the expression of ERb is
reconstituted using an inducible genetic system, the
same breast cancer cells react in a different manner to
phytoestrogen stimulation. First, the induction of
many growth-promoting transcripts involved in the
cell division cycle is attenuated compared with the
genuine 17b-estradiol response and second, there is a
stronger induction of factors that arrest cell prolifer-
ation, such as, for example, inhibitors of cyclin-
dependent kinases, thus further contributing to the
inhibition of cell proliferation.
We conclude that this attenuation of ERa-induced
expression ﬁngerprints may account for the presumed
chemopreventive activity of phytoestrogens since, as
indicated before, many of these compounds display
particularly strong afﬁnities for ERb. In view of our
ﬁndings, we propose a biphasic activity of phytoestro-
gens during cancer development in estrogen-sensitive
tissues. Thus, the presumed beneﬁcial effects of
phytoestrogens depend on the timing of exposure.
Initially, phytoestrogens are able to slow down cell
growth by activating ERb, thereby generating an anti-
proliferative expression signature. Due to the genetic
instability of malignant tumor cells, however, the
expression of ERb may be abrogated by gene deletion
or promoter methylation. In such late-stage cancer
cells, phytoestrogens, in conjunction with other
estrogenic chemicals, induce a transcriptional proﬁle
that promotes the proliferation of those clones that
exhibit high amounts of ERa but little ERb. In light of
these considerations, the potentially beneﬁcial effect of
phytoestrogens should be reevaluated, particularly in
relation to risk groups that are susceptible to the
development of ERa-positive tumors arising from
steroid hormone-dependent tissues.
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Abstract Nuclear orphan receptors 4A (NR4A) are early
responsive genes that belong to the superfamily of hormone
receptors and comprise NR4A1, NR4A2 and NR4A3. They
have been associated to transcriptional activation of multiple
genes involved in inflammation, apoptosis and cell cycle
control. Here, we establish a link between NR4As and
adenosine, a paradoxical inflammatory molecule that can
contribute to persistence of inflammation or mediate inflam-
matory shutdown. Transcriptomics screening of the human
mast cell-line HMC-1 revealed a sharp induction of transcrip-
tionally active NR4A2 and NR4A3 by the adenosine analogue
NECA. The concomitant treatment of NECA and the
adenosine receptor A2A (A2AAR) selective antagonist SCH-
58261 exaggerated this effect, suggesting that upregulation of
these factors in mast cells is mediated by other AR subtypes
(A2B and A3) and that A2AAR activation counteracts NR4A2
and NR4A3 induction. In agreement with this, A2AAR-
silencing amplified NR4A induction by NECA. Interestingly,
a similar A2AAR modulatory effect was observed on ERK1/2
phosphorylation because A2AAR blockage exacerbated
NECA-mediated phosphorylation of ERK1/2. In addition,
PKC or MEK1/2 inhibition prevented ERK1/2 phosphoryla-
tion and antagonized AR-mediated induction of NR4A2 and
NR4A3, suggesting the involvement of these kinases in AR to
NR4A signaling. Finally, we observed that selective A2AAR
activation with CGS-21680 blocked PMA-induced ERK1/2
phosphorylation and modulated the overexpression of func-
tional nuclear orphan receptors 4A. Taken together, these
results establish a novel PKC/ERK/nuclear orphan receptors
4A axis for adenosinergic signaling in mast cells, which can
be modulated by A2AAR activation, not only in the context of
adenosine but of other mast cell activating stimuli as well.
Keywords Nuclear orphan receptor 4A .Mast cells .
Adenosine . Adenosine receptor
Abbreviations
AR Adenosine receptor
HMC-1 Human mast cell line 1
NBRE-LUC Nerve-growth factor I-B responsive
element-luciferase reporter gene
NR4A1 Nuclear orphan receptor 4 A1
NR4A2 Nuclear orphan receptor 4 A2
NR4A3 Nuclear orphan receptor 4 A3
PKC Protein kinase C
RT-PCR Reverse transcriptase polymerase chain
reaction
Introduction
NR4A orphan receptors are transcription factors that belong
to the superfamily of steroid nuclear hormone receptors that
have been associated with different cellular processes,
including inflammation (Murphy et al. 2001; Pei et al.
2005), steroidogenesis (Manna et al. 2002), apoptosis
(Winoto and Littman 2002), development of dopaminergic
Concise summary Non-selective AR engagement triggers robust
induction NR4A orphan receptors in mast cells. Induction of these
early responsive genes can be blocked by selective activation of the
anti-inflammatory A2AAR not only in the context of adenosine but
also of PMA signaling, suggesting a general mechanism of mast cell
regulation.
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neurons (Zetterstrom et al. 1997) and glucose metabolism
(Pei et al. 2006b). This subfamily of nuclear orphan receptors
is constituted by 3 members: NR4A1 (also known as Nur77
or nerve growth factor inducible B, NGFI-B), NR4A2 (also
known as Nurr1) and NR4A3 (also known as NOR1). In the
context of inflammation, these factors represent NF-κB and
LPS-inducible genes in macrophages (Pei et al. 2005) and
NR4A1 expression leads to induction of inflammatory genes,
potentiating NF-κB pro-inflammatory signaling by IKKi
kinase upregulation (Pei et al. 2006a). In addition, NR4A2
has been recognized as an important inducible factor in
inflamed synovium and as a target of anti-inflammatory
effects of methotrexate (Ralph et al. 2005).
Adenosine is a purine nucleoside normally present in the
nanomolar range but its concentration in the extracellular space
rises with increased oxygen consumption during hypoxia,
tissue injury and inflammation. The rapid accumulation of
adenosine is followed by biological responses through activa-
tion of 4 types of G-coupled adenosine receptors (ARs): A1,
A2A, A2B and A3. Each of the receptor subtypes has a different
pharmacological profile, tissue distribution and effector cou-
pling profile. During chronic inflammatory processes the
sustained formation of adenosine has been associated with
deleterious effects. Elevated adenosine concentrations can be
found, for example, in bronchoalveolar lavage and exhaled
breath condesate of human patients with asthma (Driver et al.
1993; Huszar et al. 2002) where it perpetuates inflammation
and contributes to airway hyperresponsiveness. However,
activation of the A2AAR has been associated to the
suppression of inflammation and tissue remodelling (Fozard
2003; Ohta and Sitkovsky 2001) and inhibition of histamine
and tryptase release from human mast cells (Suzuki et al.
1998). However, the transcriptional effectors downstream of
AR activation responsible for adenosine’s pro or anti-
inflammatory effects remain to be characterized.
In this study, we employed the human mast cell HMC-1 to
characterize subtype specific effectors of AR activation and
we established a link between adenosine receptor activation
and nuclear orphan receptors. Furthermore, we determined
that activation of the A2AAR counterbalances the induction of
these transcription factors and that this effect is not limited to
adenosinergic signaling but that it is also conserved for other
mast cell activating stimuli. These observations describe a
novel regulatory mechanism by A2AAR, with implications in
the progression of inflammation and related pathologies.
Materials and methods
Reagents and cell culture
All chemicals were obtained from Sigma-Aldrich (Switzerland)
unless otherwise indicated. The human mast cell line-1
(HMC-1) was a kind gift from Dr. J. H. Butterfield, Mayo
Clinic, Rochester, MN, USA and was grown in Iscove’s
Modified Dulbecco’s Medium (IMDM, Invitrogen) supple-
mented with 10% iron supplemented fetal bovine serum
(Invitrogen), 1.2 mM alphathiglycerol (Sigma) and 100’000
U/l Penicillin and 100 mg/l Streptomycin (complete IMDM)
at 37°C in 5% CO2.
Cell treatments
HMC-1 cells were seeded at 8×105 cells/ml and allowed
to settle overnight. They were then treated at the indicated
concentrations with the following chemicals: the adeno-
sine analogue NECA (5′-N-Ethylcarboxamido-adenosine),
the A2AAR agonist CGS-21680 (9-Chloro-2-(2-furanyl)-
[1,2,4]triazolo[1,5-c]quinazolin-5-amine), the A2AAR an-
tagonist SCH-58261 (7-(2-phenylethyl)-5-amino-2-(2-
furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine)
and PMA (phorbol 12-myristate 13-acetate). The length of
treatment varied between 30 min and 72 h. Cells were
pretreated with 1 U/ml adenosine deaminase (Roche) to
remove any pre-existing endogenous adenosine for
20 min.
RNA extraction and cDNA synthesis
Cells were collected by centrifugation at the corresponding
time points and total RNA was recovered using the
Qiashredder and Rneasy mini kit (Qiagen). Concentration
and quality of total RNA were measured with the Ultraspec
2100 pro spectrophotometer (Amersham Biosciences).
Samples with a UV absorbance 260/280 ratio of 1.8–2.1
were considered to be suitable for cDNA synthesis. RNA
samples were stored at −20°C until use. Complementary
DNA (cDNA) was synthesized using the one-cycle cDNA
synthesis kit followed by a sample cleanup to optimize
volumes and concentration of the cDNA (GeneChip sample
cleanup module, Affymetrix).
Genome wide gene expression analysis
Global gene expression analysis was done in 4 independent
experiments, consisting of the treatment with 10 μM NECA
and untreated cells as a baseline control. After 3 h treatment
of HMC-1 cells total RNAwas extracted as described in the
previous section. The quality of RNA was determined on
the Agilent Lab-on-a-chip Bioanalyzer 2000 (Palo Alto,
USA). Samples with a total area under 28S and 18S bands
of less than 65% of total RNA, as well as a 28S/18S ratio of
less than 1.5, were considered to be degraded and therefore
excluded from microarray analysis. cRNA was synthesized
from cDNA with the IVT labeling kit (Affymetrix). cRNA
quality was assessed with the Agilent Lab-on-a-chip
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Bioanalyzer 2000. The biotin-labeled cRNA was frag-
mented and hybridized on Human Genome U122 plus
2.0 microarrays (Affymetrix), which cover sequences of
47’000 human transcripts, following the manufacturer’s
instructions. After hybridization periods of 16 h the
microarrays were automatically washed and stained on
the Affymetrix Fluidics Station 450. Staining of the
hybridized probes was performed with fluorescent
streptavidin-phycoerythrin conjugates (1 mg/ml; Molecu-
lar Probes). The subsequent scanning of DNA micro-
arrays was carried out on an Affymetrix scanner 3000
7 G. The generated data was then normalized and
subsequently filtered using a significance value of P<
0.05 using the GeneSpring 7.3.1 sofware (Agilent, Palo
Alto, CA, USA). We employed pair-wise analysis based
on B - Fabric infrastructure tool (Functional Genomics
Center Zurich, University of Zurich-Irchel, Switzerland)
and the GeneGo Metacore (www.genego.com) integrated
software for data mining and functional analysis of
experimental data. Hierarchical clustering was performed
with gplots library from CRAN.
Real time polymerase chain reaction (RT-PCR)
Specific primers for the selected transcripts as well as
TaqMan probes and TaqMan master mix were obtained
from Applied Biosystems. 40 ng of cDNA were mixed
with 1 μl of forward and reverse primers and 10 μl of
master mix supplemented with 25 nM of the
corresponding TaqMan probe in a final volume of
20 μl. The reactions were performed in a 7500 Fast
Real-time PCR-System ABI 7500 (Applied Biosystems)
in 40 cycles (95°C for 3 s, 60°C for 30 s) after an initial
20 s incubation at 95°C, and was analyzed with the 7500
Fast System SDS Software System (Applied Biosys-
tems). The fold change in expression of each gene was
calculated with the 2-Delta Delta C(T) method. Each of
these values had been normalized to the endogenous
housekeeping gene glyceraldehyde-3-phosphate dehydro-
genase (GAPDH).
Western blot
Thirty microgram of total protein in 1× Laemmli buffer
were separated on a 10% polyacrylamide gel by standard
SDS-PAGE technique from each sample, followed by
transfer onto Immune-Blot polyvinylidene difluoride
(PVDF) membranes (0.2 μm pore size, Bio-Rad) and
blocking 16 h at 4°C with blocking solution (5% non-fat
dry milk, 3% BSA in TBST (10 mM Tris, 150 mM
NaCl, 0.05% Tween 20, pH 7.4). NR4A2 and total ERK
protein levels were assessed employing a monoclonal
antibody (Alpha Diagnostic and R&D, respectively) and
phosphorylated ERK1/2 by a specific T185/Y187
phopsho-antibody (R&D, USA). GAPDH and β-actin
antibodies (Ambion, USA) were employed as internal
loading controls. Enhanced chemiluminescence was
performed with SuperSignal West Femto Maximum
(Thermo Fisher Scientific, Switzerland) and images were
acquired on a LAS-3000 image reader (Fujifilm Life
Science, Japan). NR4A2 induction was quantified by
calculating the ratio of intensity signals to GAPDH
(Quantity 1 software, BioRad) and compared to untreat-
ed controls (value=1).
siRNA silencing of A2AAR
0.4×106 HMC-1 cells in 1 ml were seeded in 24 well-
plates. Cells were transcfected with 20nM A2AAR siRNA
(Santa Cruz, Cat. sc-39850) using 4 μl lipofectamine
RNAiMax (Invitrogen) according to the manufacturer’s
instructions in Opti-MEM serum and antibiotics-free
medium. After 5 h of incubation, the medium was
replaced with complete medium. As a scramble negative
control, control (FITC Conjugate)-A siRNA (Santa Cruz,
sc-36869) was employed. Silencing of ARs was tested
by RT-PCR with specific TaqMan probes (Applied
Biosystems) as indicated above, and was maximal at
36 h. Therefore, this time point was selected for further
analysis of AR signaling.
Transient transfection and luciferase reporter gene assay
1.5×106 HMC-1 cells in 1 ml were co-transfected with the
tk-NBREx3-luc plasmid, which was a kind gift Dr. R
Evans (Howard Hughes Medical Institute, San Diego, CA)
and the pRL-TK vector (Promega, USA) at a ratio 30:1 in
serum- and antibiotics-free Iscove’s medium containing
8 μl of Lipofectamine 2000 reagent (Invitrogen). After 5 h
of incubation, the medium was replaced with complete
medium and were allowed to recover at 37°C for 24 h and
were subsequently stimulated as indicated. For luciferase
activity assay, cell lysates were prepared and assayed
using the Luciferase Assay System (Promega, USA),
according to the manufacturer’s instructions. All lumines-
cent measurements were performed automatically in a 96
well-plate in a Luminescence Spectrometer (MLX,
Dynex).
Data analysis
Statistical analysis was performed using the PASW Statis-
tics software (SPSS Inc., USA). Data were analyzed by
nonparametric tests (Mann-Whitney U-test) and differences
between groups were considered significant when p-values
were less than 0.05.
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Results
Transcriptional profiling of human mast cells reveals
upregulation of NR4A family memebers by adenosine
receptor activation
The human mast cell line HMC-1 exhibits a phenotype,
which in several aspects is similar to tissue resident mast
cells (Nilsson et al. 1994). However, these cells do not
degranulate and therefore represent a suitable system for
studying degranulation-independent de novo synthesis of
inflammatory mediators.
Previous studies have successfully used this cell line to
analyze adenosine signaling on human mast cells (Ryzhov
et al. 2006; Ryzhov et al. 2004), which prompted us to
employ a systematic genome-wide approach for the
identification of novel effector molecules involved in AR
signaling. For this, we stimulated HMC-1 cells to the
adenosine analogue NECA and 3 h after exposure the total
fraction of RNA transcripts was extracted, processed and
hybridized to Affymetrix microarrays (4 replicates). To
identify differentially expressed genes, the data sets of each
replicate were analysed in a pair-wise fashion with the
untreated controls as described in the methods section. This
analysis yielded 19 NECA-induced transcripts with fold
changes of three or higher (Table 1). The resulting heat map
reflects the degree of similarity between the individual
replicates (vertical dendogram, Fig. 1a). Gene ontology
analysis of these transcripts revealed that most of these
transcripts encode protein products involved in transcrip-
tion regulation (NR4A2, NR4A3, CREM , EGR1, 2 and 3,
FOSB, ELL2, ZEB1), signal transduction (HOMER1, ITK,
IL2RB), hormone activity (STC1, CGA), DNA metabolism
and repair (JMY, TP53INP2 ITK), cell cycle regulation
(RGC32), apoptosis (BCL2L11) and tissue remodeling
(PLAUR). Remarkably, two nuclear orphan receptors
(NR4A2 and NR4A3), which had not been associated to
adenosine signaling before, were among the highest
upregulated genes. Interestingly, the third member of
orphan receptor family, NR4A1, was induced only margin-
ally (2.05 fold). These results were confirmed by real time
RT-PCR (Fig. 1b) and suggest that NR4A2 and NR4A3
could mediate proinflammatory signaling by adenosine in
mast cells.
A2AAR inactivation amplifies NECA-mediated induction
of NR4A2 and NR4A3
Human mast cells express A2A, A2B, and A3ARs (Feoktistov
and Biaggioni 1998; Feoktistov et al. 2003). Therefore, the
observed response to NECA reflects the composite effect of
activation of all 3 receptor subtypes. Because AR subtypes
can promote (A2B and A3ARs) or downregulate (A2AAR)
inflammation, we wanted to determine the influence of
A2AAR in NR4A induction. To address this issue cells were
stimulated either with NECA, with the selective A2AAR
agonist CGS-21680, or with a combination of NECA plus
the A2AAR antagonist SCH-58261, and NR4A induction
Gene Name Description NECA FC
NR4A2 Nuclear receptor subfamily 4, group A, member 2 33.52
STC1 Stanniocalcin 1 25.37
NR4A3 Nuclear receptor subfamily 4, group A, member 3 24.13
CREM CAMP responsive element modulator 13.57
EGR3 Early growth response 3 10.16
RGC32 Response gene to complement 32 9.54
HOMER1 Homer homolog 1 (Drosophila) 7.95
FOSB FBJ murine osteosarcoma viral oncogene homolog B 6.91
CGA Glycoprotein hormones, alpha polypeptide 6.14
ELL2 Elongation factor, RNA polymerase II, 2 6.14
JMY Junction-mediating and regulatory protein 5.96
ZEB1 Transcription factor 8 5.42
EGR1 Early growth response 1 5.07
BCL2L11 BCL2-like 11 (apoptosis facilitator) 4.99
ITK IL2-inducible T-cell kinase 4.76
PLAUR Plasminogen activator, urokinase receptor 4.58
TP53INP2 p53 induced nuclear protein 2 3.88
IL2RB Interleukin 2 receptor, beta 3.78
EGR2 Early growth response 2 (Krox-20 homolog, Drosophila) 3.72
Table 1 Top regulated tran-
scripts by non-selective AR
stimulation. Cells were treated
with 10 μM NECA and fold
changes (FC) calculated against
untreated control as described
(fold change cut-off=3,
P<0.005)
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was assessed by RT-PCR. Figure 2a and b show time-
dependent induction of NR4A2 and NR4A3. While NECA-
mediated induction of NR4A2 and NR4A3 reached maximal
induction of 240-fold and 98-fold respectively 1 h after
treatment, selective activation of A2AAR with 1 μM CGS-
21680 did not induce them. In contrast, blockage of A2AAR
with the combined treatment of NECA and SCH-28261,
results in further upregulation of these nuclear receptors,
with fold changes up to 429 and 376 over the untreated
controls respectively. These observations point out that the
induction of these two transcription factors rely on the
activation of non-A2A ARs. Interestingly, NECA plus SCH-
58261 did not upregulate NR4A1 further when compared to
NECA (4.2-fold, Fig. 2c), indicating that this interplay
between non-selective and selective A2AAR activation is
not conserved to the third member of this family of
receptors. Also, induction of the cAMP-response element
modulator (CREM, a top-regulated gene from the tran-
scriptomics screening, see Table 1) reaches 55-fold when
treated with NECA, while CGS-21680 or the combination of
NECA plus SCH-58261 induce CREM only marginally,
indicating that simultaneous activation of all ARs is required
to achieve maximal CREM induction (Fig. 2d).
To confirm the role of A2AAR dependent changes in
NR4A2 and NR4A3 expression, HMC-1 cells were trans-
fected with A2AAR-specific siRNA, which led to 63%
silencing 36 h after transfection (Fig. 3a). Treatment of
A2AAR silenced cells with NECA resulted in higher
NR4A2 expression levels as compared to mock silenced
cells, mimicking the effect of pharmacological blockage of
A2AAR with the combination of NECA plus SCH-58261
(Fig. 3b). Altogether, these results indicate that activation of
A2AAR counterbalances NR4A2 and NR4A3 induction by
A2BAR and A3AR.
Adenosine receptor activation increases NR4A2 protein
abundance
Next, we wanted to determine whether AR-mediated
increment of NR4A2 mRNA levels translate into changes
in protein abundance. Western blot analysis of NR4A2
protein revealed that NECA treatment results in a remark-
able induction of this factors reaching maximal levels at
12 h, with values returning to background levels 24 h after
exposure (Fig. 4). As expected, selective A2AAR activation
with CGS-21680 did not upregulate NR4A2 (not shown).
However, induction of NR4A2 protein by the concomitant
treatment of NECA plus SCH-58261 was higher than with
NECA but also returned to basal levels within 24 h. These
results confirm that transcriptional upregulation of NR4A2
by AR activation results in increased protein levels.
AR-induced NR4As are transcriptionally active
In view of the strong induction of NR4A2 and NR4A3, we
performed a functional assay based on an exogenous
reporter gene to determine how the activity of these factors
is affected by AR activation. NR4A receptors bind to the
octanucleotide 5′-A/TAAAGGTCA (NGFI-B response ele-
ment, NBRE) and therefore we employed an NBRE-
luciferase reporter plasmid (tk-NBREx3-luc) and quantified
luciferase induction upon AR activation. Figure 5 shows
Fig. 1 a Hierarchical clustering analysis of transcriptional changes of
HMC-1 cells induced by NECA. Each column represents a single
experiment (4 replicates for each condition, untreated and treated with
10 μMNECA, 3 h) and contains all genes that were significantly
upregulated in at least one of replicates and a minimum induction of 3
fold. The resulting vertical dendrogram indicates the degree of
similarity between different transcriptomes. Expression levels are
expressed in a log 2 scale and transcripts with values of 5 or lower
(blue and light blue) are marginally expressed or absent. Repeated
gene names indicate different probe sets for a single gene (different
expression signals for alternative probe sets could indicate alternative
splicing or poor probe performance). b Confirmation of NR4A induction
by RT-PCR. Fold changes are calculated in relation to untreated
controls. Values represent the mean of three experiments ± SEM
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time-dependent induction of luciferase activity upon treat-
ment with NECA, CGS-21680 or NECA in combination
with SCH-58261. Both NECA and NECA plus SCH-58261
induced a robust response, which peaked between 12 h and
24 h with nearly a 30- and 40-fold reporter induction as
compared to untreated controls respectively. NBRE reporter
activity decreased sharply by 48 h and returned to
background values 72 h after treatment. On the contrary,
CGS-21680, did not induce luciferase expression signifi-
cantly. Interestingly, reporter induction by NECA plus
SCH-58261 was not statistically significantly higher than
by NECA, despite the remarkable difference in induction of
these transcription factors. This discrepancy can be
explained by the intrinsic limitations of the artificial
reporter gene system employed. The luciferase construct
includes a minimal promoter region in the 5′-regulatory
Fig. 4 Western blot analysis of NR4A2. HMC-1 cells were treated
with 10 μM NECA, or the combination of 10 μM NECA and 1 μM
SCH-58261 (SCH) for the indicated time points. GAPDH is included
as an internal control. Fold change of NR4A2 protein (FC) are
calculated from the ratio to GAPDH and compared to baseline
expression in untreated cells (lane 1)
Fig. 3 Effect of A2AAR silencing on NR4A2 induction. a Transfec-
tion of HMC-1 cells with A2AAR-siRNA (A2AAR si) specifically
downregules this receptor subtypeation of A2AAR. Scramble siRNA
was included as a control b A2AAR silenced cells were treated with
for 2 h with 10 μM of NECA or 10 μM of NECA plus 1 μM SCH-
58261 (SCH). Values represent the mean of three independent
experiments ± SEM
Fig. 2 Time dependent induc-
tion of NR4A2 (a), NR4A3 (b),
NR4A1 (c) and CREM (d).
Cells were treated with 10 μM
NECA, 1 μM CGS-21680
(CGS) or 10 μM NECA plus
1 μM SCH-58261 (SCH) and
RNA was collected at the indi-
cated time points and analyzed
by RT-PCR. Fold changes are
calculated against untreated
controls. Values represent the
mean of three independent
experiments ±SEM
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region of the NBRE repeats. Therefore, this assay may not
allow the full response (gene expression) that could be
expected in the context of endogenous chromatin to take
place, thereby limiting the amplitude of the responses
measured and of the differences between treatments.
Nevertheless, these results confirm that AR activation
induces transcriptionally active NR4As that could have
profound biological implications.
AR-mediated NR4A2 and NR4A3 upregulation
involves PKC and MEK kinases, and correlates
with A2AAR-, PKC- and MEK-sensitive ERK1/2
phosphorylation
NR4As can be induced by a variety of stimuli, which are
signaled through diverse intracellular regulators in a cell
type and stimulus-dependent fashion (Martinez-Gonzalez
and Badimon 2005). Therefore, we wanted to determine the
intracellular signaling pathways participating in NR4A2
and NR4A3 induction by ARs. To address this issue we
interrogated the role of the mitogen-activated kinase p38,
protein kinase A (PKA), phosphoinositide 3 kinase (PI3K),
protein kinase C (PKC) and MEK kinase with selective
inhibitors, by assessing the AR-mediated induction of
NR4A2 and NR4A3 (NECA plus SCH-58261). While
30 min pretreatment with SB203580 (p38 inhibitor), H89
(PKA inhibitor) and wortmannin (PI3K inhibitor) did not
affect NR4A induction, blockage of either PKC or MEK
with GF109203X or PD98059 respectively partially
reverted AR-mediated induction of these factors (Fig. 6a).
Based on previous reports that showed that ERK phosphor-
ylation is involved in AR inflammatory signaling in HMC-
1 cells (Feoktistov et al. 1999), and because ERK1/2 is a
downstream target of PKC, we wanted to determine
whether activation of A2AAR correlates with ERK phos-
Fig. 5 Time-dependent induction of NBRE by AR engagement. The
results are shown as ratio against the respective untreated control. For
each measurement the ratio between the reporter gene (firefly) between
and the internal Renilla standard was calculated (three independent
determinations). Cells were treated with 10 μM NECA, 1 μM CGS-
21680 (CGS) or 10 μM NECA plus 1 μM SCH-58261 (SCH)
Fig. 6 Effect of kinase inhibi-
tors on AR-mediated NR4A
induction and ERK1/2 activa-
tion a Pretreatment with MEK
and PKC inhibitors partially
reversed NR4A2 and NR4A3
induction by 10 μM NECA and
1 μM SCH-58261. 0.5 μM
SB203580 (SB), 1 μMH89,
0.1 μM wortmannin (Wt),
100 μM PD98059 (PD) or
10 μM GF109203X (GF) were
employed for preincubation. b
A2AAR-blockage excacerbates
NECA-induced phosphorylation
of ERK1/2 (N+SCH). This ef-
fect is blocked by preincubation
with PD98059 (PD) and
GF109203X (GF) in a concen-
tration dependent way
Selective regulation of NR4A receptors 4 A by adenosine receptors
37
phorylation. NECA readily induced phosphorylation of
ERK1/2 while CGS-21680 did not (Fig. 6b, lanes 2 and 3).
Interestingly, NECA plus SCH-58261 resulted in exaggerated
ERK1/2 phosphorylation (lane 4), demonstrating an inverse
relationship between A2AAR activation status and ERK1/2
phosphorylation. Furthermore, this pattern of ERK phos-
phorylation could be reverted by preincubation with
GF109203X or with PD98059 in a concentration dependent
manner (lanes 5–8). Taken together, these results indicate
that PKC and MEK kinases are required for AR-dependent
ERK1/2 phosphorylation and NR4A2 and NR4A3 upregu-
lation, and that activation of A2AAR opposes ERK1/2
activation by other ARs.
A2AAR activation modulates PMA-induced ERK
phosphorylation, NR4A2 and NR4A3 induction
and NBRE transcriptional activity
Next, we wanted to assess whether A2AAR activation is
able to influence NR4A induction by stimuli other than
adenosine. Therefore, we selected PMA, a diester of
phorbol that acts as a PKC activator, which is a central
regulatory molecule with a role in cytokine production,
arachidonic acid release and mast cell degranulation (Chang
et al. 1997; Cho et al. 2004). Stimulation of HMC-1 cells
with PMA resulted in robust ERK1/2 phosphorylation that
could be reverted with increasing concentrations CGS-
21680 (Fig. 7a). In addition, 1 μM CGS-21680 significant-
ly decreased PMA-mediated NR4A2 and NR4A3 induction
(by 35 and 53% respectively, Fig. 7b) and, moreover, levels
of PMA-induced NR4A2 protein were also reduced
(Fig. 7c). In light of these findings, we tested whether
A2AAR activation could affect the transcriptional activity of
PMA-induced NR4As, by means of the NBRE-LUC
reporter assay. Remarkably, preincubation with 1 μM
CGS-21680 caused a significant reduction in PMA-
induced NBRE-LUC activity (35%, Fig. 7d).
Altogether, these results show that the inhibitory effect
of A2AAR on nuclear orphan receptor 4A stimulation is
conserved beyond adenosinergic inflammatory signaling
and that activation of this receptor can regulate intracellular
signaling by other inflammatory stimuli.
Discussion
Mast cells have been traditionally associated to immediate-
type hypersensitivity reactions through the release of
preformed inflammatory mediators. However, in recent
years it has become clear that these cells can regulate
immune responses through de novo synthesis of cytokines,
chemokines, and eicosanoids without degranulation (differ-
ential release inflammatory mediators), supporting a role of
Fig. 7 Effect of A2AAR activation on PMA-mediated NR4A activity.
a Increasing concentrations of CGS-21680 (CGS) antagonize PMA-
induced ERK1/2 phosphorylation. β-Actin is included as an internal
control, b Reduction of PMA-mediated NR4A2 and NR4A3 tran-
scriptional induction by increasing concentrations of CGS-21680
(CGS). Values are relative to induction by PMA and indicate the
mean of three independent experiments ± SEM. *, **: p<0.05 for
reduction in NR4A2 and NR4A3 induction respectively (Mann-
Whitney U test), c Western blot analysis of NR4A2 induced by
PMA alone or with the indicated concentrations of CGS-21680, d
CGS-21680 (CGS) reduces the transcriptional activity of PMA-
mediated NBRE-LUC reporter activity. For each measurement the
ratio between the reporter gene (firefly) and the internal Renilla
standard was calculated. Values are relative to LUC expression by
PMA, and represent the mean of three independent experiments ±
SEM. PMA concentration in all experiments was 50 nM. *p<0.05 for
NBRE-LUC activity reduction (Mann-Whitney U test)
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mast cells in more persistent (chronic) inflammatory and
immunological responses such as chronic bronchitis and
asthma-related pulmonary inflammation (Brightling et al.
2003; Church and Levi-Schaffer 1997), renal injury (Mack
and Rosenkranz 2009), and tumorigenesis (Blatner et al.
2010; Groot Kormelink et al. 2009).
The engagement of activating and inhibitory cell-surface
receptors, as well as the intensity and duration of these
signals, will determine the activation state of mast cells; in
response to these stimuli, gene expression patterns of
inflammatory mediators are altered according to the sum
of positive and negative signaling events, thereby affecting
the course of inflammation. Based on adenosine’s ability to
both positively and negatively regulate mast cell activation
through the engagement of alternate AR subtypes, it has
been argued that selective activation of the A2AAR (anti-
inflammatory) or blockage of A2BAR and A3AR (proin-
flammatory) may represent a pharmacological tool for
modulating their adenosinergic inflammatory signaling.
However, transcriptional effectors downstream of ARs
responsible for adenosine’s pro- or anti-inflammatory
effects remained to be fully characterized.
In this study we present a novel link between AR
activation and NR4A orphan receptors in human mast cells,
and we show that selective activation of the A2AAR can
negatively regulate the induction of these factors. Our
initial genome-wide screening revealed strong upregulation
of NR4A2 and NR4A3. Recent evidence shows that
NR4A2 induction represents a common point of conver-
gence of distinct cytokine signaling pathways, suggesting
an important common role for this family of transcription
factors as mediating inflammatory signaling (McEvoy et al.
2002). Therefore, we reasoned that the anti-inflammatory
A2AAR could influence the expression of these pro-
inflammatory factors. In fact, we observed that the concom-
itant treatment with the A2AAR antagonist SCH-58261
significantly amplified NECA’s effect on NR4A2 and
NR4A3 induction. In view of the pleiotropic physiological
roles of NR4As, adenosine’s effect on this group of
transcription factors could have broad biological implications.
In contrast to other members of the nuclear hormone
receptor superfamily, the crystal structure and NMR data
indicate that the ligand-binding pocket of NR4A receptors
is covered by hydrophobic residues (Wang et al. 2003). In
fact, these receptors have been shown to function as ligand-
independent transcription factors that are constitutively
active and whose activity is controlled at the level of
protein expression and post-translational modifications
(Codina et al. 2004; Fahrner et al. 1990). For this reason,
adenosine’s effects on the abundance of these transcription
factors could have immediate biological implications. On one
hand, the activation of pro-inflammatory ARs (i.e. A2B and
A3ARs) in inflammatory cells could act as an amplification
signal resulting in even higher levels of NR4As and in the
expression of a larger set of NBRE-responsive genes. On the
other, A2AAR activation could mediate inflammation reso-
lution indirectly by limiting the expression of NR4A2 and
NR4A3-dependent inflammatory genes.
NR4As also influence the function of other inflammation-
associated transcription factors. For example, NR4A1 and
NR4A2 form heterodimers with retinoic acid receptor and
can influence retinoid signaling (Wallen-Mackenzie et al.
2003). Therefore, AR activation could affect the number of
NR4A-containing complexes: AR-mediated accumulation
of NR4A2 and NR4A3 would translate in a higher
proportion of transcriptional complexes containing these
orphan receptors. Conversely, A2AAR activation would
limit the availability of NR4A2 and NR4A3 for hetero-
dimerization with other TFs. In addition, NR4A receptors
can also crosstalk with other TFs and influence their
activity without necessarily interacting with them. A recent
study has established that NR4A receptors and the
estrogen-related receptors NR3B mutually repress each
others transcriptional activity (Lammi et al. 2007). Similar-
ly, NR4A1 has been shown to negatively cross-talk with
NF-κB (Harant and Lindley 2004). As a consequence, by
virtue of the induction of reamarkably high levels of
functional NR4A2 and NR4A3, adenosine is likely pro-
foundly affect the expression of large sets of genes both
directly (NBRE-responsive transcripts) and indirectly, by
affecting the nature of transcriptional complexes and/or
crosstalking with other TFs.
Activation of mast cells (for example by the high affinity
IgE receptor) requires the activation of receptor-proximal
tyrosine kinases, mobilization of internal Ca2+ and the
formation of signaling complexes coordinated by adaptor
proteins (Rivera and Gilfillan 2006). PI3K is a central player
in mast cell activation that signals to regulatory molecules
such as PKC and phospholipases C and D (PLC and PLD)
among others, which ultimately regulate mast cell degranu-
lation, arachidonic acid metabolite production and cytokine
gene transcription. AR activation has traditionally been
linked to stimulation or inhibition of the adenylyl cyclase;
A2AAR and A2BAR activation lead to increased cAMP
levels that in turn activate the canonical PKA pathway and
the exchange protein directly activated by cAMP (Epac)
(Palmer and Trevethick 2008), while A1AR and A3AR
activation leads to cAMP decrease (Zhou et al. 1992). In
addition, AR signaling in mast cells has also been linked to
PLC and calcium mobilization (A2BAR and A3AR), PI3K
(A3AR), as well as PKC and MAP kinases (A1, A2A and
A3AR) (Jacobson and Gao 2006; Spicuzza et al. 2006).
Several intracellular regulators have been linked to
NR4A induction (Martinez-Gonzalez and Badimon 2005).
In this study we established that AR-mediated NR4A2 and
NR4A3 upregulation in HMC-1 did not involve PKA nor
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PI3K nor p38. Instead, PKC and MEK kinase inhibition
could partially revert the induction of these factors and,
moreover, the activity of these kinases correlated with
ERK1/2 phosphorylation. Interestingly, some studies have
also shown the involvement of ERKs in adenosine
signaling (Feoktistov et al. 1999) but downstream targets
of ERK upon AR activation had remained elusive. The
results presented here suggest that activation of ERK1/2
kinases downstream of PKC mediates NR4As induction by
AR. Remarkably, A2AAR can counterbalance NECA-
induced ERK1/2 phosphorylation, correlating with its
modulatory effect on NR4A2 and NR4A3 induction.
However, blockage of PKC and a complete inhibition of
ERK phophorylation resulted only in about a 50% decrease
NR4A2 and NR4A3 induction, suggesting the involvement
of at least one additional intracellular signaling pathway in
AR-dependent nuclear orphan receptor upregulation in mast
cells. The contribution of other intracellular signaling
pathways remains to be investigated.
Finally, we examined whether the antagonistic effect of
A2AAR on ERK1/2 phosphorylation and NR4A2 and
NR4A3 induction is preserved to other mast cell activating
stimuli, by the concomitant activation of A2AAR and mast
cell stimulation with PMA. Strikingly, A2AAR engagement
resulted not only in a modulation of PMA-mediated ERK1/
2 phosphorylation, but also limited NR4A2 and NR4A3
induction, and their activity as assessed by the NBRE-LUC
reporter assay. These results show that A2AAR modula-
tory’s effect on the ERK1/2-NR4A signaling axis is not
limited to adenosinergic signaling.
Taken together, the results presented in this study
establish a novel effector signaling axis downstream of
adenosine, and suggest NR4A antagonism as a mechanism
mediating A2AAR anti-inflammatory effects in mast cells.
Thus, this data contributes to the understanding of how
receptor-specific signals are integrated towards modulation
of the inflammatory response, which could facilitate the
development of AR-based strategies of immunomodulation.
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Abstract
Adenosine is a purine nucleoside whose concentration increases during inﬂammation and hypoxia and the many roles of this molecule
are becoming better understood. Increased reactivity to adenosine of the airways of asthmatic but not of normal subjects underlines the
role of adenosine in airway inﬂammation. The identiﬁcation and pharmacological characterisation of diﬀerent adenosine receptors have
stimulated the search for subtype-speciﬁc ligands able to modulate the eﬀects of this molecule in a directed way. Several compounds of
diﬀerent chemical classes have been identiﬁed as having potential drawbacks, including side eﬀects resulting from the broad distribution
of the receptors across the organism, have prevented clinical application.
In this article, the eﬀects of adenosine’s diﬀerent receptors and the intracellular signalling pathways are reviewed. The potential of
adenosine receptor modulation as a therapeutic target for chronic airway inﬂammation is considered, taking equine recurrent airway
disease and feline asthma as examples of naturally occurring airway obstructive diseases. Other potential applications for adenosine
receptor modulation are also discussed. As the intrinsic molecular events of adenosine’s mechanism of action become uncovered, new
concrete therapeutic approaches will become available for the treatment of various conditions in veterinary medicine.
 2007 Elsevier Ltd. All rights reserved.
Keywords: Adenosine; Adenosine receptors; Signal transduction; Chronic airway inﬂammation; Veterinary inﬂammatory conditions
Introduction
Adenosine is an endogenous nucleoside consisting of the
purine base adenine in glycosidic linkage with the sugar
ribose. Adenosine is present at low concentrations in the
extracellular space and its concentration is greatly
increased under metabolically stressful conditions as a
result of enzymatic cleavage of the nucleotide adenosine
5 0-monophosphate (AMP) by the 5 0-nucleotidase (Arch
and Newsholme, 1978). For example, an increase in aden-
osine formation occurs during inﬂammation when a large
number of inﬁltrating inﬂammatory cells compete for a
limited oxygen supply (Fig. 1). Intracellular concentrations
of adenosine are kept low principally by its conversion to
AMP by the enzyme adenosine kinase, but it may also be
degraded to inosine by adenosine deaminase (Trams and
Brown, 1974).
In mammals, adenosine can be released as the result of
hypoxia, tissue injury and acute or chronic inﬂammation
reaching local concentrations of up to 30 lM – a 150-fold
increase over basal levels (Van Belle et al., 1987). Increased
adenosine is found in bronchoalveolar lavage (BAL) and
exhaled breath condensate of human patients with asthma
(Driver et al., 1993; Huszar et al., 2002). Intracellular pro-
duction of adenosine is increased during these stressful
conditions and then transported across the membranes
where it exerts its activities upon binding to adenosine
receptors (ARs) (Thorn and Jarvis, 1996). The nucleoside
mediates tissue protection by diﬀerent mechanisms includ-
ing increased oxygen supply/demand, ischemic precondi-
tioning and stimulation of angiogenesis, and also as a
paracrine inhibitor of inﬂammation with eﬀects in the lung,
heart and brain.
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Adenosine and inﬂammation
Persistent inﬂammation is a central feature of many dis-
eases and invariably involves the recruitment and activa-
tion of inﬂammatory cells that lead to structural changes
in the aﬀected organs. In diseases of the lung, for example,
over 100 inﬂammatory mediators have been implicated,
and the blocking of a single mediator is unlikely to be eﬀec-
tive. In fact, antagonists for these molecules have so far
proved less eﬀective than drugs with a broad spectrum of
anti-inﬂammatory eﬀects, such as glucocorticoids (Leckie
et al., 2000). In recent years, the involvement of several fac-
tors acting as global stimulators or inhibitors has become
better understood, thus opening new avenues for drug dis-
coveries. Adenosine is one such molecule with therapeutic
potential as an inﬂammatory modulator. For this reason,
there is growing interest in elucidating the mechanisms by
which adenosine inhibits the immune system, since these
inhibitory adenosine receptors and their downstream sig-
nalling pathways are promising targets for new anti-inﬂam-
matory therapy in veterinary medicine.
G-coupled adenosine receptors
Four types of adenosine receptors (ARs) have been
identiﬁed: A1, A2A, A2B, and A3. ARs have the typical
topological structure of G-protein-coupled receptors
(GPCR) with a central core domain consisting of seven
transmembrane helices connected by three intracellular
and three extracellular loops (Fig. 2). ARs have been
cloned and characterised in several experimental animals,
but information about the receptors in some other species
of veterinary importance is limited. For example, in the
cat, the sequence of just a fragment of the A3AR is known,
while in the horse, only the A2AAR and A3AR have been
cloned (Brandon et al., 2006a,b).
Receptors A1AR, A2BAR, and A3AR are among the
smallest members of the GPCR family and possess a simi-
lar number of amino acids composing their primary struc-
ture. For example, the canine homologues of A1AR,
A2BAR, and A3AR consist of 326, 332, and 314 amino acid
residues, respectively. Conversely, the canine A2AAR is
composed of 412 amino acids. All cloned species homo-
logues of the A2AAR are of similar mass, and this relatively
large size is manifested in the carboxyl-terminal tail of the
receptor, which is much longer than that of the other AR
subtypes. The human A1AR and human A3AR display
ca. 49% overall sequence identity at the amino acid level,
while the human A2AAR and human A2BAR are 45%
identical.
The identiﬁcation of discrete receptor regions, or even
single amino acids that contribute to ligand recognition
and are responsible for discerning between agonist and
antagonist ligands, has been an area of extensive investiga-
tion. Both transmembrane and extracellular regions of
ARs have been implicated as playing a role in the forma-
tion of the ligand-binding pocket and several amino acids
that contribute to the ligand-binding properties have been
identiﬁed via mutagenesis (for review, see Moro et al.,
2006). Discovering ligand–receptor interactions at a molec-
Fig. 1. Cycle of adenosine synthesis and degradation. Adenosine is formed from catalytic cleavage of cyclic AMP by endo- (N) or ecto-nucleotidases (EN).
Once in the interstitium, adenosine binds and activates adenosine receptors, resulting biological eﬀects. Adenosine is degraded by adenosine deaminase
(AD) to inosine or it is recycled to AMP by adenosine kinase. Inﬂammation and hypoxia increase AMP concentrations.
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ular level will not only allow understanding the details of
the process, but will also provide the basis for rational drug
design.
Signal transduction and transcriptional eﬀectors
Although the bioavailability of adenosine is an impor-
tant determinant of its biological functions, the pattern of
expression and distribution of ARs in the anatomical–
structural sites of tissues and organs accounts for the obser-
vation that adenosine may exert either deleterious or pro-
tective roles. Adenosine receptors are expressed in a wide
variety of tissues and each of the four subtypes so far has
a unique pharmacological proﬁle, tissue distribution and
eﬀector coupling. They exert their distinct eﬀects by inter-
acting with diﬀerent G-proteins, which mediate activation
or inhibition of the enzyme adenyl cyclase and therefore
a change in the intracellular concentration of cAMP. In
addition, other pathways, such as phospholipase C
(PLC), Ca2+ and mitogen-activated protein kinases (MAP-
Ks), are involved in adenosine signalling (Fig. 3).
The anti-inﬂammatory eﬀects of the A2A receptor
appear to depend on its coupling to Gs (and to Golf in stri-
atum in the brain), stimulation of the adenylate cyclase and
the consequent increase in intracellular cAMP. The A2BAR
couples both to Gs, promoting cAMP accumulation, and
to Gq triggering Ca
2+ mobilization and activation of
PLC and MAPKs (Gao et al., 1999). Interestingly, cross-
talk between Gs and Gq appears to regulate interleukin
(IL)-4 production by A2B in human mast cells (Ryzhov
et al., 2006). The arachidonic acid pathway has also been
implicated in A2B signalling (Donoso et al., 2005). The
A1 and A3ARs can inhibit the adenyl cyclase by coupling
to Gi, but in addition they can activate K
+ and Ca2+ chan-
nels (Cronstein, 1994).
Interspecies diﬀerences in adenosine receptor-speciﬁc
eﬀects have been observed. For example, pharmacological
diﬀerences between the rat and guinea pig A2BAR and
the canine adenosine A2B receptor have been determined
by using subtype-speciﬁc antagonists (Fozard et al.,
2003). Species variations in the A3AR binding properties
of xanthine antagonists have also been identiﬁed (Salvatore
et al., 1993). In this context, the A2A receptor appears to be
unique since, to date, all reports show that this receptor has
anti-inﬂammatory eﬀects, independently of the species.
Several publications have proposed that inhibition of
NF-jB activity, a well-characterised pro-inﬂammatory
transcription factor, is the direct target of cAMP-mediated
AR anti-inﬂammatory eﬀects. Genetic evidence in A2AAR
deﬁcient mice indeed shows that an increase in pro-inﬂam-
matory cytokines at the transcriptional level in these ani-
mals is associated with enhanced NF-jB activity
(Lukashev et al., 2004). In the absence of A2AAR, adeno-
sine can mediate a decrease in TNF-a independently of
NF-jB, suggesting that adenosine’s immunomodulatory
eﬀects depend on other transcriptional factors (Nemeth
et al., 2003).
A recent report has suggested that another transcription
factor, the nuclear factor of activated T cells (NFAT), can
integrate signals originated from A2B coupled to Gq and Gs
and transduced by cAMP and IP3 respectively (Ryzhov
et al., 2006). Downstream components of the JNK activa-
tion pathway have been reported to be up-regulated in
asthma (Demoly et al., 1995) along with enhanced
Fig. 2. Theoretical 3D-structure of the ARs. This model has been constructed using the high-resolution structure of rhodopsin as a template (Kim et al.,
2003). The transmembrane helical domains are represented in red, while the intra- and extracellular loops are represented in grey. The adenosine-binding
pocket is shown in blue. Note that the intracellular C-terminus end of the A2AAR (not depicted) is composed of about 80–100 additional residues.
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NF-jB activation in both asthma and chronic obstructive
pulmonary disease (COPD) (Hart et al., 1998; Di Stefano
et al., 2002). Similarly, sustained NF-jB activity has been
associated with recurrent airway disease in horses (see
below). Therefore, inhibition of MAPK and NF-jB appear
to be suitable molecular targets for chronic airway inﬂam-
matory conditions. The architecture of signal transduction
is represented in Fig. 3.
The complexity of these ﬁndings illustrate the highly
intricate network of adenosine signal transduction, which
we are only starting to elucidate, and points to the need
to systematically address the role of each player implicated
in adenosine signalling.
AR agonists and antagonists
The search for potent and selective adenosine receptor
ligands has been one of the most highly investigated areas
in recent medicinal chemistry. While several analogues
have been derived from adenosine itself (by modiﬁcations
both at the adenine and ribose moieties), other more selec-
tive agonists have been obtained by empirical and semi-
rational molecular modelling approaches. These strategies
have brought up a large number of chemicals with diﬀeren-
tial aﬃnity for the AR subtypes.
Interestingly, the eﬃcacy at A3AR is more easily dimin-
ished by structural modiﬁcation than it is at the other sub-
types and, therefore, adenosine derivatives have provided
an alternative approach to the design of A3 antagonists.
For example, compounds substituted with large groups
such as CCPA display full agonist eﬀect at A1 but behave
as a moderately potent A3 antagonist (Gao and Jacobson,
2002). Agonists for the A2B receptor have remained elusive
but recently, compounds with an improved selectivity pro-
ﬁle for the human A2BAR have been reported (Beukers
et al., 2004).
Conversely, xanthines represented the starting point for
the discovery of potent and more selective AR antagonists.
In addition, screening chemical libraries allowed the identi-
ﬁcation of non-xanthine polyheterocyclic derivatives with
AR antagonist properties. These include an impressively
wide range of dihydropyridines, ﬂavinoids, thiazoles and
imidazoline derivatives among others. Xanthines are non-
selective AR blockers, with theophylline and caﬀeine dis-
playing micro molar aﬃnities for A1-, A2A- and A2BARs;
aﬃnity for the A3AR is lower, in the high micro molar
range (Zhou et al., 1992). A major physico-chemical limita-
tion of xanthines is their low water solubility and great
emphasis has been placed in improving this property. As
a result, several xanthine derivatives with improved water
solubility have been successfully designed.
The eﬀects of various AR ligands have been character-
ised in diﬀerent animal species. Table 1 summarises the
most relevant ﬁndings grouped by receptor type and com-
pound. Notably, pronounced interspecies diﬀerences in the
pharmacology of both AR agonists and antagonists have
Fig. 3. Signal transduction pathways of ARs. Upon ligand binding, ARs couple to G-proteins and several signalling pathways become activated
ultimately resulting in a ﬁnely tuned transcriptional response. ai, as, aq, b and c are subunits of G-protein. PLC, phospholipase C; PKC, protein kinase C;
MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; PI3K, phosphoinositide 3-kinases; PKB/AKT, protein kinase B;
NF-jB, nuclear factor-jB; PKA, protein kinase A; CREB, cAMP response element binding.
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Table 1
Adenosine receptor agonists and antagonists, whose pharmacological characteristics have been tested in animal studies
Class Compound Species, organ Pharmacological eﬀect Remarks Reference
Agonists
A1 CCPA Cat, regional vascular bed Vasodilatation Bivalacqua et al. (2002)
CPA Cow, corneal endothelium Increased cAMP and endothelial
ﬂuid transport
Tan-Allen et al. (2005)
A2A NECA Horse, digital veins Vasodilatation Elliott and Brady (1998)
Dog, mast cells Degranulation Proposed to act
through A2BAR
activation
Auchampach et al. (1997)
CGS21680 Equine receptor,
heterologous expression in
HEK cells
Inﬂammation down-regulation Brandon et al. (2006a)
Dog, exocrine pancreas Water and bicarbonate secretion Iwatsuki (2000)
CVT-3146 Dog, myocardium Vasodilatation No renal
vasoconstriction
Zhao et al. (2003)
ALT-146e Dog, myocardium Reduction of infarct size in a canine
model of myocardial infarction
Glover et al. (2007)
A2B LUF5835 N/A N/A –
A3 IB-MECA Equine, heterologous
expression in HEK cells
Inﬂammation down-regulation Brandon et al. (2006b)
Cat, lung arteries Reduction of ischemic injury Rivo et al. (2004)
Dog, myocardium Reduction of infarct size after
ischemic injury by preconditioning
Auchampach et al. (2003)
Antagonists
A1 DPCPX Horse, forebrain N/A Chou and Vickroy (2003)
Cat, pulmonary vascular bed Inhibition of vasoconstrictor
responses of adenosine at low
vascular tone
Neely and Matot (1996)
Feline, oesophageal smooth
muscle cells
Inhibition of adenosine-mediated
contraction
Shim et al. (2002)
Sheep, respiratory system Increased ventilation in normoxic
conditions
Koos et al. (2005)
CPX,
BG9928
Dog, myocardium Reduction of infarct size in a canine
model of myocardial infarction
Auchampach et al. (2004)
KW3902 Dog, kidney Prevention of ischemia-reperfusion
injury (A1-mediated)
Li et al. (2005)
Diuresis and natriuresis Kobayashi et al. (1993)
A2A ZM241385 Horse, striatum (forebrain) N/A Chou and Vickroy (2003)
Equine receptor,
heterologous expression in
HEK cells
Perpetuation of inﬂammation Brandon et al. (2006a)
Sheep, respiratory system Inhibition of hypoxic ventilatory
adaptive response
Koos et al. (2005)
Cat and dog, cardiovascular Reversion of adenosine-mediated
blood pressure and vasodilatory
eﬀects
Poucher et al. (1996)
A2B 8-SPT, XAC,
CGS15943,
CGH2473
Dog, saphenous vein smooth
muscle
Inhibition of NECA-induced muscle
contraction (an AR-agonist)
NECA response
in this model
appears to be
A2B- mediated
Fozard et al. (2003)
A3 MRS1191 Cat, lung arteries Prevention of AR-mediated
protection of reperfused
lung
Rivo et al. (2004)
N/A: no information available.
Abbreviations: ALT-146e: four-{3-[6-amino-9-(5-ethylcarbamoyl-3,4-dihydroxytetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-cyclohexanecarboxylic
acid methyl ester; BG9928: (3-[4-(2,6-dioxo-1,2-dipropyl-2,3,6,7- tetrahydro-1H-purin-8-yl)-bicyclo [2,2,2]oct-1-yl] propionic acid; CPA: N6-cyclopen-
tyladenosine; CCPA: 2-chloro-N6-cyclopentyladenosine; CGH2473: N-[4-(3,4-dichloro-phenyl)-5-pyridin-4-yl-thiazol-2-yl]-acetamide; CGS15943:
9-chloro-2-(2-furyl[1,2,4]triazolo[1,5-c]quinazolin-5-amine; CGS21680: 2-[4-[(2-carboxyethyl)phenyl]ethylamino]-5-N-ethylcarboxamidoadenosine; CPX:
8-cyclopentyl-1,3-dipropyl-xanthine; CVT-3146: (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-
methylcarboxamide; DPCPX: 8-cyclopentyl-1,3,dipropylxanthine; IB-MECA: N(6)-(3-iodobenzyl)-adenosine-5 0-N-methylcarboxamide; KW3902: 1,
3-dipropyl-8-(3-noradamantyl)xanthine; LUF5835: 2-amino-4-(4-hydroxyphenyl)-6-(1H-imidazol-2-ylmethylsulfanyl)pyridine-3,5-dicarbonitrile;
MRS1191: 3-ethyl-5-benzyl-2-methyl-4-phenylethynykyk-6-phenyl-1,4-(±)-dihydropyridine-3,5 dicraboxylate; NECA: 5 0-(N-ethylcarboxamido) adeno-
sine; XAC: xanthine amine congener; ZM241385: 4-(2-[7-amino-2-(2-furyl)[1,2,4] triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol; 8-SPT: 8-sulpho-
phenyltheophylline.
42 R.G. Dip / The Veterinary Journal 179 (2009) 38–49
47
been observed. The xanthine derivative DPCPX, for exam-
ple, is highly potent and about 500-fold more selective for
A1 compared with the A2A in a rat model (Lohse et al.,
1987), whereas in humans this compound shows higher
aﬃnity towards the A2A and the A2B receptors.
A study comparing the A2B-mediated muscle relaxant
eﬀect of AR antagonists of diﬀerent classes showed similar
aﬃnities for the rat and guinea pig receptor, while for some
compounds a weaker aﬃnity for the dog receptor was
recorded (Fozard et al., 2003). In the case of the sheep
and human A3AR, they bind xanthines with intermediate
aﬃnity, while the rat A3AR shows much lower aﬃnity
for these compounds (Yang et al., 2005). These ﬁndings
indicate that important species-dependent responses should
be expected and such pharmacological heterogeneity
should be taken into consideration at the diﬀerent phases
of compound development.
Adenosine in the lung: an inﬂammatory mediator with
diﬀerential biological eﬀects
There is growing evidence that adenosine plays an
important role in respiratory disorders associated with lung
inﬂammation. Adenosine (but not its metabolite inosine or
the unrelated nucleoside guanosine) administered by inha-
lation was shown to be a powerful bronchoconstrictor of
asthmatic but, importantly, not of normal airways (Cush-
ley et al., 1983). Similarly, a recent study has established
that the administration of adenosine 5 0-monophosphate
provoked airﬂow limitation in dogs with cadmium chlo-
ride-induced airway inﬂammation but not on healthy indi-
viduals (Hirt et al., 2007). Increased formation of
adenosine occurs in chronically inﬂamed airways as dem-
onstrated by elevated levels of adenosine both in BAL ﬂuid
and exhaled breath condensate of human patients with
asthma with elevations correlating with the degree of
inﬂammatory insult (Driver et al., 1993; Huszar et al.,
2002).
Several ﬁndings have suggested that this nucleoside con-
tributes as a mediator of bronchoconstriction in asthma.
First, it was shown that adenosine is released into the cir-
culation following allergen challenge of sensitised individu-
als (Holgate et al., 1980). Second, blockade of adenosine
re-uptake by dipyridamole increased the bronchoconstric-
tor response to adenosine in asthma indicating that accu-
mulation of extracellular adenosine was closely associated
with the asthmatic airway response (Cushley et al., 1985).
This has led to the current hypothesis that release of hista-
mine and other spasmogens from resident airway mast cells
may account for the bronchoconstrictor response to
inhaled adenosine in asthma (Spicuzza and Polosa, 2003).
Nevertheless, the role of histamine in similar pathologies
in other species (i.e. recurrent airway obstruction in horses
and feline asthma, see below) is less clear with antihista-
minic agents showing erratic therapeutic eﬀects.
Lung mast cells are known to be critical eﬀector cells in
the mediation of asthma and adenosine can inﬂuence their
function. In vitro studies conﬁrmed that adenosine and A2
receptor analogues (e.g. 5 0-N-ethylcarboxamideadenosine,
NECA) could augment IgE-dependent mediator release
from human mast cells (Church et al., 1982; Forsythe
et al., 1999). More recently it has been shown that adeno-
sine also upregulates Th2 cytokines in mast cells promoting
IgE synthesis by B lymphocytes, suggesting that adenosine
not only participates with mast-cell derived mediators dur-
ing bronchoconstriction but that it also contributes to the
maintenance of inﬂammation (Ryzhov et al., 2004).
Even though the mechanism by which cyclic nucleotides
regulate the function of mast cells is not well understood,
and that diﬀerent subtypes of receptor seem to be involved
in diﬀerent species, these ﬁndings postulate AR ligands as
promising therapeutic agents for the treatment of allergic
asthma and other IgE-mediated diseases.
Adenosine receptors as targets in pulmonary disorders
Adenosine has long been recognised to inﬂuence the
function of diﬀerent cell types through activation of ARs.
The high aﬃnity A1AR has been implicated in both pro-
and anti-inﬂammatory aspects of disease processes. In the
lung, A1AR activation has been implicated in the regula-
tion of bronchoconstriction in allergic rabbit models (Ali
et al., 1994), suggesting a provocative role for A1AR signal-
ling in acute phases of asthma. Similarly, A1AR antago-
nism has been shown to be beneﬁcial in attenuating
ischemia reperfusion and endotoxin-induced lung injury
(Neely and Keith, 1995; Neely et al., 1997). However, the
genetic removal of A1AR from adenosine deaminase-deﬁ-
cient mice cause enhanced pulmonary inﬂammation along
with increased mucus metaplasia and alveolar destruction,
implicating a protective role for adenosine (Sun et al.,
2005). Further studies need to be conducted to reconcile
these apparently contradictory ﬁndings.
Signalling by A2A is unequivocally linked to anti-inﬂam-
matory eﬀects in the lung. For example, selective activation
of the A2AAR by the compound CGS-21680 produces
broad-spectrum anti-inﬂammatory activity in a rat model
of allergic asthma, suggesting that agonists could be useful
in the treatment of this disease (Fozard et al., 2002). Also,
CGS-21680 is able to protect the lung of Sprague–Dawley
rats against shock-induced injury, implicating a novel ther-
apeutic approach in preventing organ injury following
trauma/hemorrhagic shock (Hasko et al., 2006).
Several lines of evidence suggest that the A2BAR is dee-
ply involved in the mechanisms by which adenosine induces
bronchoconstriction and airway inﬂammation in asthma.
Human mast cells have been shown to respond to
A2BAR stimulation by producing and releasing cytokines
(Feoktistov and Biaggioni, 1995; Ryzhov et al., 2004).
Also, pharmacological in vitro studies have shown that
A2B receptor antagonists can eﬀectively inhibit adenosine-
induced activation and degranulation of mast cells (Feok-
tistov et al., 2001). In light of these observations, the
R.G. Dip / The Veterinary Journal 179 (2009) 38–49 43
48
development of selective adenosine A2B antagonists has
considerable therapeutic potential.
In the case of the A3AR receptor, interspecies variation
appears to play an important role. While abundantly
expressed in rodent mast cells, apparently mediating
degranulation in the rat and guinea pig (Zhong et al.,
2003), A3 receptors are found on human eosinophils, neu-
trophils and monocytes, where they seem to inhibit degran-
ulation (Ezeamuzie and Philips, 1999; Gessi et al., 2002).
Interestingly, IB-MECA, an A3 agonist, has been able to
attenuate the indices of injury and apoptosis following lung
reperfusion in an isolated cat lung model. Furthermore,
these eﬀects could be blocked by the administration of
MRS1191, a dyhydropyrimidine that is a selective A3
antagonist (Rivo et al., 2004). On the other hand, it has
been shown that the canine A3 AR is structurally and phar-
macologically more similar to the human than to the rat
receptor (Auchampach et al., 1997).
Naturally occurring recurrent airway obstruction in animals:
therapeutic potential of AR modulation in veterinary
medicine
Equine recurrent airway obstruction (RAO, previously
known as COPD): Recurrent airway obstruction (RAO),
also known as heaves, shares pathophysiological features
with chronic asthma in humans, characterised by broncho-
spasm, mucus secretion, airway hyper-reactivity, and air-
way wall thickening together with deterioration of lung
function (Robinson et al., 1996; Tsoumakidou et al.,
2004). The major diﬀerence between these two diseases is
that in heaves neutrophils dominate BAL ﬂuids, as
opposed as eosinophils in asthma. Even so, mast cells, mac-
rophages and lymphocytes can be recovered by BAL from
RAO-aﬀected horses (Rush et al., 1998; Lavoie et al.,
2001).
Several ﬁndings have established a close parallel
between the two pathologies. First, histamine has been pro-
posed as the main vasoactive mediator in this disease, with
concentrations in BAL correlating with the numbers of
mast cells and/or basophils. In addition, horses with a his-
tory of heaves have been found to be hyper-reactive to aer-
osol histamine during acute exacerbations (Derksen et al.,
1985). Other autacoids including serotonin, leukotrienes,
thromboxane and 15-HETE have also been implicated
(McGorum et al., 1993; Franchini et al., 1998), although
the role of these mediators in RAO can be questioned
because neither antihistamine nor non-steroidal anti-
inﬂammatory treatments improve lung function. Second,
allergen-speciﬁc IgE and IgG levels can be measured in
horses with heaves, suggesting that hypersensitivity may
be the cause of RAO, as occurs in human and feline asthma
(Eder et al., 2000; Ainsworth et al., 2002). In fact, elevated
mRNA levels of IL-4, IL-5 but decreased levels of inter-
feron (IFN)-c have in measured in BAL-recovered cells
from heaves-aﬀected horses (Lavoie et al., 2001), suggest-
ing a seemingly polarised T-helper 2 cytokine proﬁle and
therefore an allergic condition with similarity to asthma.
Other cytokines with altered proﬁles in RAO include IL-
1b, tissue necrosis factor (TNF)-a and IL-8 (Giguere et al.,
2002; Ainsworth et al., 2003), and IL-17 (Debrue et al.,
2005). Finally, the downstream eﬀects triggered by these
cytokine proﬁles are driven by common transcription fac-
tors. For example, IL-1b and TNF-a appear to be respon-
sible for the persistent pro-inﬂammatory NF-jB activity in
bronchi of horses with RAO – a characteristic ﬁnding in
asthmatic airways (Bureau et al., 2000). Other transcription
factors that have been associated with asthma and RAO
are AP-1, GATA-3 and CREB (Adcock, 1997; Nguyen
et al., 2003; Couetil et al., 2006).
In view of the similarities between heaves and asthma, it
could be hypothesised that adenosine plays a comparable
role in the pathogenesis of both diseases. One early report
showed that adenosine inﬂuences contractility in healthy
equine tracheal smooth muscle (Norris and Eyre, 1982).
To the best of our knowledge, no study has focused on
the role of adenosine in the physiopathology RAO nor
has the potential of AR modulation been assessed in this
condition.
Recently, equine A2AAR has been cloned in a heterolo-
gous system, where it inhibited NF-jB’s activity in a con-
centration dependent fashion (Brandon et al., 2006a).
The availability of these and other molecular biology tools
will allow the development and validation of AR ligands
with therapeutic potential for RAO in the horse.
Feline asthma
Feline asthma is one of the most common diseases of the
lower respiratory tract in cats and has an extraordinary
resemblance to human asthma. It involves bronchocon-
striction, early and late allergen-induced airway responses,
eosinophilia, airway wall remodelling and chronic inﬂam-
mation, and it has been considered an ideal model of
human asthma. Interestingly, airway inﬂammation can
occur even in symptom-free asthmatic cats, indicating the
need of appropriate therapy directed toward decreasing
the underlying chronic inﬂammatory component of the dis-
ease (Padrid, 2000).
Studies on experimental models of asthma in cats have
contributed to understanding the immunological events
occurring during the spontaneously developing disease in
the cat. Employing a Bermuda grass sensitization model,
Norris Reinero et al. (2004) identiﬁed a T helper type 2
cytokine proﬁle in BAL cells, together with airway eosino-
philia and allergen-speciﬁc IgE, IgG and IgA both in serum
and in BAL, with resemblance to both the ﬁndings in
human and equine RAO (with the exception of the eosino-
philia). Studies in Ascaris suum-sensitised cats revealed that
serotonin (and not histamine) released upon mast cell
degranulation appears to be the main autacoid involved
in bronchoconstriction (Padrid et al., 1995), explaining
the unpredictable eﬀects of inhaled histamine on cats
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aﬀected with feline asthma. A recent study using this model
determined a signiﬁcant increase of enhanced pause (Penh,
an index of bronchoconstriction) accompanied with radio-
graphic and bronchoscopic alterations indicative of active
remodelling together with elevated F2-isoprostane concen-
tration and MMP-9 activity in BALF (Kirschvink et al.,
2007). The later two factors have been proposed as biolog-
ical markers of lung inﬂammation and tissue remodelling
and are also elevated in human asthma and COPD (Atkin-
son and Senior, 2003; Morrow and Roberts, 2002).
Remarkably, A2AAR activation inhibits MMP-9 secretion
by neutrophils (Ernens et al., 2006).
Therefore, although further studies in cats (both on
spontaneously occurring and on experimental animals)
are clearly needed to conﬁrm the involvement of adenosine
in the pathophysiology in these species, the overall similar-
ities with human asthma suggest that AR modulation
could represent an attractive option for the treatment of
asthma in this species.
Adenosine receptors modulation: more than airway
inﬂammation
Beside their eﬀects in cells of the immune system, ARs
have been postulated as pharmacological targets for the
treatment of several diseases. Some applications with
potential in veterinary medicine are listed below.
Acute endotoxemia
Endotoxin plays a pivotal role in many pathophysiolog-
ical states and diseases, and their recognition by cells of the
immune system through Toll-like receptors results in
downstream activation of NF-jB and MAPK pathways.
In turn, pro-inﬂammatory cytokines are expressed,
resulting in a coordinated biological response. During
endotoxemia, the expression and release of cytokines (e.g.
TNF-a) becomes deregulated, resulting in an uncontrolled
inﬂammatory loop. The role of the A2A receptor was ﬁrst
observed in A2AAR knock-out mice, which showed an
exacerbated inﬂammatory phenotype upon administration
of an endotoxic stimulus (aseptic), uncovering a
non-redundant mechanism for the down-regulation of
inﬂammation (Ohta and Sitkovsky, 2001). A recent study
has established that A2AAR agonists can selectively inhibit
the production of H2O2 in polymorphonuclear leukocytes
isolated from septic shock patients (Kaufmann et al.,
2007), underscoring the potential of this approach for the
treatment of systemic inﬂammatory states.
Modulation of the pro-inﬂammatory activity of NF-jB
appears to be the main downstream eﬀect of A2AAR.
Recently, Brandon et al. (2006a) cloned and expressed
the equine A2AAR in a heterologous system and character-
ised its aﬃnity to AR ligands. Employing a reporter gene
assay, they showed that activation of the equine A2AAR
with the speciﬁc agonist CGS21680 reduces NF-jB tran-
scriptional activity in a concentration-dependent manner.
This pioneer work constitutes the base for future studies
to examine the potential of A2AAR modulation in the
treatment of systemic inﬂammation in horses.
Ischemia–reperfusion injury
One of the most intensively investigated eﬀects of aden-
osine is its protective action on reperfusion injury after
ischemia. Several studies have shown the potential of tar-
geting ARs for myocardial infarction treatment, as well
as for lung and hepatic reperfusion injury. Diﬀerent ARs
appear to be involved in this response and accumulating
evidence suggests that hepatic reperfusion injury is trig-
gered by lymphocyte activation of A2ARs on bone mar-
row-derived cells (Day et al., 2004, 2005). A recent study
has shown that initiation of the reperfusion-induced
inﬂammatory cascade is dependent on IFN-c production
by NKT cells and that A2A agonists can decrease the pro-
duction of IFN-c in this cell type (Lappas et al., 2006).
Ischemic preconditioning by adenosine could potentially
ameliorate the eﬀects of reperfusion injury in liver, pan-
creas, intestine and myocardium in diseases such as gastric
dilatation and volvulus (GDV) in dogs, arterial thrombo-
embolism in cats or gastrointestinal ischemic injury in
horses. In dogs, for example, the A3 receptor agonist IB-
MECA has proven eﬀective in reducing infarction size in
an in vivo model of myocardial ischemia (Auchampach
et al., 2003). Myocardial ischemia and reperfusion injury
can lead to arrhythmia during GDV (Buber et al., 2007),
indicating that ischemic preconditioning by adenosine
receptor ligands could have a direct application in veteri-
nary medicine.
Interestingly, adenosine could have additional pharma-
cological advantages in the heart of dogs with GDV by
improving myocardial perfusion, and also by its direct anti-
arrhythmic eﬀects (see below). Whether these experimental
ﬁndings will translate into useful therapies for the treat-
ment of pathological states associated with ischemia and
reperfusion in veterinary medicine remains to be seen.
Arthritis
The A3AR agonist IB-MECA has been shown to down-
regulate inﬂammation in a murine arthritis model after oral
administration and to ameliorate the clinical and histopa-
thological manifestations of adjuvant-induced arthritis in
rats, in which A3ARs were highly expressed (Fishman
et al., 2006; Rath-Wolfson et al., 2006). Overexpression
of A3ARs was also detected in peripheral blood mononu-
clear cells of human patients with rheumatoid arthritis
and receptor upregulation appears to be induced by inﬂam-
matory cytokines controlling the expression of the tran-
scription factor NF-jB (Madi et al., 2007). Even though
no information is at this point available implicating a role
for adenosine (and A3ARs) in immunomediated arthropa-
thies in veterinary medicine, these recent ﬁndings may
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reveal new and exciting approaches for the treatment of
these pathologies.
Vasodilatation
Adenosine is a potent vasodilator in most vascular beds,
except in renal aﬀerent arterioles and hepatic veins where it
produces vasoconstriction. Adenosine (as Krenosin) has
been indicated for myocardial perfusion scintigraphy in
humans. The A2AAR has been shown to be involved in
vasodilatation in the aorta and coronary artery. In fact,
the A2AAR agonist CVT-3146 has been proved a selective
coronary vasodilator in dogs with minimal systemic hae-
modynamic eﬀects, making it an attractive alternative for
myocardial perfusion imaging (Zhao et al., 2003).
ARs as targets in renal disorders
Several lines of evidence support a protective eﬀect of
A1AR activation in the kidney (for a recent review, see Val-
lon et al., 2006). For example, mice lacking A1ARs show a
completely blocked renal glomerular ﬁltration rate, as well
as increased renal injury after ischemia and reperfusion
(Sun et al., 2001; Lee et al., 2004). These ﬁndings provide
the basis for the development of drugs with great potential
for the treatment of renal failure in both human and veter-
inary medicine.
ARs and the CNS
The observation that caﬀeine (a classical AR antagonist)
enhances awareness and other activities on the nervous sys-
tem at lower doses than those required for blocking phos-
phodiesterases, has stimulated the investigation of the
eﬀects of AR modulation in the central nervous system.
A2A- and A1ARs are the primary mediators of the behav-
ioural stimulatory eﬀects of caﬀeine. These two receptor
subtypes have been identiﬁed in the forebrain tissue of
horses and their pharmacological proﬁles have been evalu-
ated (Chou and Vickroy, 2003). In this study, caﬀeine and
related methylxanthines were shown to antagonise CNS
actions of adenosine eﬀectively.
Several AR antagonists are being tested for the treat-
ment of various nervous system disorders in humans (some
at advanced clinical trial stages) ranging from Parkinson’s
disease to dementia and sleep disorders. Whether these
ﬁndings will translate into concrete therapies in veterinary
medicine remains to be seen.
Arrhythmia
The antiarrhythmic eﬀect of adenosine (as Adenocard,
Fujisawa) has been exploited in human medicine for sev-
eral years to restore the normal rhythm in patients with
paroxysmal supraventricular tachycardia (Zablocki et al.,
2004). In contrast, relatively high doses of adenosine have
been ineﬀective in abolishing supraventricular tachycardia
in dogs (Wright, 2000). Moreover, practical issues such as
its short half-life and the need to administer it very rapidly
through a central vein have limited its application in veter-
inary medicine.
The antiarrhythmic eﬀect of adenosine is mediated by
A1AR activation, which reduces heart rate and atrial con-
tractility and also attenuates the stimulatory action of cat-
echolamines. Several A1AR agonists are in advanced
development stages for this application, without the side
eﬀects of other AR subtypes (i.e. hypotension). The avail-
ability of these selective compounds may result in improved
pharmacological options for the treatment of selected
arrhythmias in veterinary medicine.
The future of AR modulation in veterinary medicine
With the availability of pharmacological probes and
knockout models for most of the four AR subtypes, the
implications of adenosine signalling are now been recogni-
sed. In the past, undesirable side eﬀects associated with the
wide tissue distribution of ARs have often prevented candi-
date drugs from performing successfully in clinical trials.
This has remained a challenge for medicinal chemistry
and we are now only starting to see compounds in
advanced phases of development for the treatment of spe-
ciﬁc conditions.
Even if our understanding of the role of adenosine in
veterinary medicine has lagged behind, the development
of novel molecular biology research tools will allow us to
assess the therapeutic potential of AR modulation in spe-
cies of veterinary interest, primarily for the treatment of
chronic airway inﬂammatory diseases but also for a myriad
of other conditions.
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Abstract 
Several lines of evidence showing the involvement of adenosine in the pathogenesis 
of chronic airway conditions have led to new therapeutic strategies to limit airway 
inflammation. In this study, detectable levels of adenosine in bronchoalveolar lavage 
(BAL) samples from 11 horses with non-infectious lower-airway inflammation and 14 
healthy controls are reported, with significantly higher values in airway-compromised 
horses. Although these increased levels did not correlate with changes in neutrophil 
percentage in BAL fluid, a positive association between adenosine levels and signs 
of lower airway inflammation (clinical score) was observed. These findings suggest, 
first, that adenosine could be considered a marker of equine airway inflammation with 
diagnostic value and, second, that this nucleoside plays a role in respiratory disease 
in this species, advocating for the development of new strategies for the treatment of 
equine lower airway inflammation based on the regulation of this signalling axis.  
 
Keywords: horse; airway inflammation; adenosine; bronchoalveolar lavage  
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In recent years, the role of adenosine signalling in airway inflammation has become 
better understood. This endogenous nucleoside is a metabolic by-product that 
accumulates in BAL and exhaled breath condensate in patients with asthma (Driver 
et al., 1993; Huszar et al., 2002). Inhalatory administration of adenosine induces 
bronchoconstriction of asthmatic but not of normal airways, and in addition to this 
effect, adenosine modulates the course of inflammation through the release of 
cytokines and chemokines from various cell types in the airways (Caruso et al., 
2009). Therefore, strategies based on adenosine receptor ligands are currently being 
developed aimed at controlling adenosine-mediated inflammatory signalling (Dip, 
2009). 
Persistent inflammation is a central feature of chronic non-infectious airway 
conditions in the horse such as recurrent airway obstruction (RAO) and inflammatory 
airway disease (IAD) (Robinson, 2001). Therefore, we wanted to ascertain whether 
adenosine signalling is associated with inflammation in the equine lower airways. 11 
adult horses (3 mares and 9 geldings; age range 7–17 years, median= 9.5 years) 
that were presented with mild to moderate signs of lower airway inflammation at the 
Equine Clinic at the University of Zurich were included in the study. Symptoms 
included exercise intolerance, coughing, nasal discharge and were diagnosed with 
lower airway inflammatory disease (either IAD or RAO) on the basis of history, 
clinical findings, mucus and cytological examination of BAL samples. Animals that 
were medicated less than 28 days prior to the examination as well as those with 
concomitant signs of infectious or systemic disease were excluded from the study. In 
addition, 14 healthy controls (4 mares and 10 geldings; age range 5–22 years, 
median= 11 years) with no history of airway inflammation or clinical signs of 
respiratory disease and normal BAL cytology were employed as a control group. 
Each horse was clinically examined and given a weighted score, using a scale with 
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range 0 to 25 as described by (Tesarowski et al., 1996). All clinical observations were 
done by 2 individuals, which were blinded to the group identity of the horses.  
Bronchoalveolar lavage was performed as described (Zhang et al., 2010). For 
cytological analysis, cytospin slides were prepared, stained with May-Grünwald 
Giemsa and at least 400 cells from each sample were counted. In addition, BAL-
samples were collected in vials containing 0.1μM iodotubericidin and 10μM of the 
erythro-9-(2-hydroxy-3-nonly)adenine (Sigma), centrifuged and cell-free fractions 
immediately frozen. All samples were analyzed by a specific spectrometry-based 
assay at a later time point (Ren et al., 2008). Urea concentration was determined 
both in BAL and serum samples obtained simultaneously (QuantiChrom assay, 
BioAssay Systems), and the ratio between these values was employed as an 
indicator of epithelial lining fluid dilution and employed for adenosine concentration 
normalization. BAL cytology, clinical score and normalized adenosine concentration 
are summarized in table 1. 
Every BAL sample analysed revealed adenosine levels clearly above the limit of 
detection (LOD: 0.02 pg/mL BAL). Furthermore, adenosine concentration was 
significantly higher in airway-compromised horses (range 26.4-377.3 pg/mL, median 
112.8 pg/mL) as compared to healthy controls (range 17-191 pg/mL, median 43.6 
pg/mL), suggesting a role for this nucleotide in the development of lower airway 
inflammation in this species (Fig. 1).  
Because the determination of lower airway inflammation in the horse relies heavily on 
clinical findings and BAL cytology (in addition to medical history), we hypothesized 
that adenosine concentration could be associated to the degree inflammation when 
assessed by these criteria. Fig. 2A shows the relationship between adenosine 
concentration in BAL and clinical score for the horses studied. All healthy controls 
had a clinical score of 2 or lower (average: 0.6) and with the exception of one horse, 
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adenosine values were below 130 pg/mL. On the other hand, elevated clinical scores 
(average: 4.6) were related to higher adenosine concentrations in airway-
compromised horses. Statistical analysis indeed revealed a positive correlation 
between adenosine concentration and clinical score. 
The assessment of cytological alterations in BAL, in particular neutrophil count, 
remains a major diagnostic tool in equine airway disease (Couetil et al., 2001). In 
fact, the percentage of neutrophils serves as an indicator of the severity of the 
underlying inflammation. In this study, however, a correlation between adenosine 
concentration and neutrophil count could not be established (Fig. 2B). As a matter of 
fact, all but one of the samples with adenosine levels over 200 pg/mL showed 
marginal to moderate increments in neutrophil numbers, suggesting no association 
between these variables. Yet, this observation should be interpreted with care 
because only three samples with neutrophil count indicative of moderate to severe 
airway inflammation (more than 20%) were tested. Analysis of a larger set of 
samples with high percentage of neutrophils (i.e. acute RAO phase) would be 
required to clarify the relationship between these two parameters. 
The presence of increased adenosine concentrations in airway-compromised horses 
would suggest that adenosine could represent a marker of inflammation. However, in 
view of the partial overlap in the values of both groups of horses analyzed, 
assessment of adenosine levels in BAL does not seem to be suitable as the sole 
indicator of disease, but should be interpreted in combination with other diagnostic 
parameters (i.e. clinical signs).  
The data presented suggest the presence of an adenosine signaling axis in the 
equine airways. Two lines of evidence support this hypothesis. On one hand, an 
early report indicated that adenosine influences contractility in equine tracheal 
smooth muscle (Norris and Eyre, 1982). On the other, we recently showed enhanced 
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IL-6 transcriptional responses to adenosine receptor ligands in BAL cells from horses 
with lower airway inflammation (Zhang et al., 2010). Therefore, the high adenosine 
levels reported here suggest that this nucleoside not only contributes to 
bronchoconstriction during disease, but that it also acts as a pro-inflammatory 
mediator in the bronchoalveolar milieu of airway-compromised horses.  
Altogether, our findings indicate that adenosine plays a role in equine respiratory 
disease and argue for the development of new strategies for the treatment of highly 
prevalent lower airway inflammatory conditions, such as RAO and IAD. 
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Figure legends 
 
Fig. 1. Adenosine concentration in BAL fluid samples in airway-compromised and 
control horses. *: P≤0.05, between groups (Mann-Whitney U-test). 
 
 Fig. 2. A) Positive correlation between adenosine concentration and clinical score 
for all 25 horses included in the study (Spearman r correlation coefficient, P≤0.05; 
slope: 0.01823). B) Association between adenosine concentration and neutrophil 
count. No correlation was observed. (): horses diagnosed with lower airway 
inflammation. ( ): healthy controls.    

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Enhanced IL-6 transcriptional response to adenosine
receptor ligands in horses with lower airway inﬂammation
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Summary
Reasons for performing study: Accumulation of extracellular
adenosine has been closely associated with human asthmatic
responses. However, the relevance of adenosine signalling in
equine airways has not previously been investigated.
Objectives: To determine the expression of adenosine receptors
(AR) in bronchoalveolar lavage (BAL) cells and assess the
reactivity of these cells to AR ligands ex vivo, employing IL-6
as readout of adenosinergic inflammatory signalling.
Methods: Eight horses with varying degrees of lower airway
inflammation and 10 healthy controls were analysed.
Expression of AR-subtypes in each BAL sample was
determined by quantitative RT-PCR and compared to
that in 13 other tissues. Bronchoalveolar lavage cells were
stimulated either with the adenosine analogue NECA, CGS-
21680 (A2AAR selective agonist) or with a combination
of NECA and SCH-58261 (A2AAR antagonist) and IL-6
expression assessed.
Results: Bronchoalveolar lavage cells predominantly expressed
A2BAR, with lower A2AAR levels and marginal A3AR
expression; A1AR was not detected. This pattern was similar
to that of PBMCs but different from the other tissues tested.
No significant differences in AR expression in BAL cells from
both groups were detected, although a trend for decreased
A2BAR in airway-compromised horses was observed.
Treatment of BAL cells with the nonselective agonist
NECA upregulated IL-6 expression in cells from airway-
compromised horses, but levels remained unchanged in
control animals. Furthermore, blockage of A2AAR with SCH-
58261 enhanced IL-6 mRNA induction by NECA in both
groups, with higher levels in airway-compromised horses; the
amplitude of this response correlated with neutrophil count.
Conclusions: These results demonstrate the presence of an
adenosine/IL-6 inflammatory axis in the bronchoalveolar
milieu of airway-compromised horses. While A2BAR is
the predominant proinflammatory AR subtype expressed,
A2AAR appears to modulate inflammatory signalling (IL-6
expression) by adenosine.
Potential relevance: This study supports selective AR targeting
as a potential therapeutic approach for the modulation of
inflammation in the equine lower respiratory tract.
evj_350 1..8
Introduction
Chronic inflammatory airway diseases are remarkably prevalent in
the horse. Recurrent airway obstruction (RAO) and inflammatory
airway disease (IAD) are 2 such conditions that share a number of
clinical, cytological and functional similarities. Recurrent airway
obstruction is characterised by bronchospasm, mucus secretion,
airway hyperreactivity and airway wall thickening together with
deterioration of lung function and affects older individuals, while
IAD-affected horses are usually younger with clinically milder
signs (Couetil et al. 2007).
Adenosine is an endogenous byproduct of ATP metabolism
normally present at low concentrations in the extracellular space.
Its levels are greatly increased under metabolically stressful
conditions such as tissue injury, hypoxia and acute or chronic
inflammation, reaching local concentrations of up to 30 mmol/l,
a 150-fold increase over basal levels (Van Belle et al. 1987). This
nucleoside activates 4 types of G-coupled adenosine receptors
(ARs), which are expressed on various inflammatory and stromal
cells: A1, A2A, A2B and A3. ARs have well characterised anti-
inflammatory and wound healing activities, demonstrating the
importance of these signalling pathways in tissue protection
(Hasko et al. 2008). In some situations, however, adenosine
generation and AR activation have proinflammatory activities
that amplify tissue injury (Blackburn 2003). These observations
have driven research efforts to develop selective agonists or
antagonists for AR subtypes for use in novel therapies for chronic
inflammatory conditions.
There is growing evidence that adenosine plays an important
role in respiratory disorders in the lower airways. Increased amounts
of adenosine are found in bronchoalveolar lavage and exhaled breath
condensate of human patients with asthma (Driver et al. 1993;
Huszar et al. 2002) and,when administered by inhalation, adenosine
was shown to be a powerful bronchoconstrictor in asthmatics
but not in healthy subjects (Cushley et al. 1983). Furthermore,
blockade of adenosine reuptake by dipyridamole increased the
bronchoconstrictor response to adenosine in asthma indicating that
its accumulation is closely associated with the asthmatic airway
response (Cushley et al. 1985).
Recent studies have investigated the adenosine pathway in
the horse. The affinity of several ligands to AR subtypes has been
studied in horse neutrophils (Sun et al. 2007). Equine A2A and
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A3ARs have been cloned in this species (Brandon et al. 2006a,b).
Furthermore, activation of A2AAR in equine monocytes has
been shown to inhibit lipopolysaccharide-induced TNF-a
production, suggesting a therapeutic potential for AR modulation
in inflammation (Sun et al. 2008a). However, the relevance of
adenosine signalling on the regulation of inflammatory cytokines
in the equine respiratory tract has not previously been examined.
Here, we employed an ex vivo approach to assess the role of
adenosine in the physiopathology of lower airway inflammation
in the horse. First, we established the expression profile of ARs
in BAL cells and compared it to cerebellum, cortex, myocardium,
aorta, spleen, stomach, jejunum, caecum, kidney, adrenal gland,
eye, fat and peripheral blood mononuclear cells (PBMCs). Second,
we determined that AR levels do not differ significantly between
compromised and control animals. Third, we investigated the
reactivity of BAL-recovered cells from horses with lower airway
inflammation and healthy controls to AR ligands and determined
that nonselective pharmacological activation of ARs leads to
increased expression of the pro-inflammatory cytokine IL-6 in
cells from horses with lower airway inflammation but not from
control animals. Finally, we observed that selective blockage of
A2AAR further increases IL-6 transcription, leading to remarkably
high levels in horses with lower airway inflammation. These
data suggest that adenosine signalling is a relevant inflammatory
mechanism during lung inflammatory conditions and that A2AAR
acts as an endogenous modulator of inflammatory signalling in the
equine airway.
Materials and methods
Horses
Eight adult horses (2 mares and 6 geldings; age range 5–18 years,
median = 13 years; weight range 450–516 kg) were presented
with varying degrees of lower airway inflammation at the Equine
Clinic at the University of Zurich. Clinical signs included exercise
intolerance, coughing, nasal discharge and the horses were
diagnosed with lower airway inflammatory disease (either IAD
or RAO) on the basis of history, clinical findings, mucus and
cytological examination of BAL samples.
Ten healthy horses with no history of airway inflammation or
clinical signs of respiratory disease and normal BAL cytology were
employed as a control group (7 mares and 3 geldings; age range
8–17 years, median = 9 years; weight range 480–605 kg). These
horses belonged to the same stud, were vaccinated and dewormed
regularly, stabled in the same barn and fed hay and grain twice
a day. Sample collection of control horses was approved by the
veterinary district authorities; anaylsis of samples obtained for
diagnostic purposes did not require approval.
Bronchoalveolar lavage and differential cytology
Horses were sedated with a combination of xylazine (0.1 mg/
kg bwt i.v.)1 and butorphanol (0.02 mg/kg bwt i.v.)2. A fibroscope
was introduced into a nostril, directed into the trachea and
advanced until it wedged in a bronchus. During the advancement of
the bronchoscope the bronchial surface was continuously
anaesthetised with 50 ml of a solution containing 0.4% lidocaine
and 0.9% sodium chloride injected through a sterile catheter passed
through the biopsy channel. Two-hundred-and-fifty ml of
prewarmed (37°C) sterile physiological saline solution were then
infused into the bronchus and immediately reaspirated into a sterile
glass flask kept on ice.
Bronchoalveolar fluid was centrifuged at 200 g for 10 min and
rinsed x1 with PBS.A cytospin slide was prepared and stained with
May-Grünwald Giemsa for cytological analysis. At least 400 cells
from each lavage sample were counted.
Cell culture and ex vivo stimulation
The remaining cells were resuspended in Dulbecco’s Modified
Eagle’s Medium (DMEM), supplemented with 10% FBS3, 0.1 u/ml
penicillin and 0.1 mg/ml streptomycin3 at a concentration of 2 ¥
106/ml, 106 cells were seeded in each well of a 24 well plate
and cultured overnight at 37°C under humidified air containing
5% CO2. The following day cells were treated for either 3 h
with the AR ligands 5′-N-ethylcarboxamidoadenosine (NECA,
10 mmol/l), 2-p-(2-carboxyethyl)phen ethylamino-NECA (CGS-
21680, 0.1 mmol/l) or the combination of NECA and 5-amino-
7-(2-phenylethyl)-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]
pyrimidine (SCH-58261, 1 mmol/l). All chemicals were from
Sigma4. The use of lidocaine as a local anesthetic during the BAL
procedure did not contribute to any observed effect as there was an
extensive rest period before the cells were used.
RNA extraction and cDNA synthesis
Total RNA was isolated and cDNA synthesised as described
(Franchini et al. 2000). Briefly, RNA was isolated using the
total RNA isolation kit, which includes a DNAse treatment
step5. RNA concentration was measured by optical density
at 260 nm and RNA quality assessed by 260/280 absorvance ratio
and cDNA synthesised with the cDNA reverse transcription kit6
following the manufacturer’s instructions. Briefly, 0.5 mg of total
RNA was mixed with 1 ml of random primers, 2 ml of reverse
transcription buffer and 0.8 ml dNTP mix, 1 ml multiScribe reverse
transcriptase and 1 ml RNA inhibitor to a final volume of 20 ml. The
mix was incubated at 25°C for 10 min and at 37°C for 120 min and
then heated at 85°C for 5 s. The reactions were stored at -20°C until
used.
Samples for adenosine receptor expression profiling
Immediate post mortem samples were obtained from one healthy
horse. 200 mg of cerebellum, cortex, myocardium (left ventricle),
aorta, spleen parenchyma, jejunum and caecum (submucosa and
muscular), kidney (cortex), adrenal (cortex and medulla), eye
(conjunctiva) and retroperitoneal fat were mechanically disrupted
in a 3 ml Dounce homogeniser in lysis buffer5. Additionally, 10 ml
of whole blood were obtained from this animal and PBMCs
isolated employing a Ficoll reagent, following the manufacturer’s
instructions7. Ribonucleic acid from each tissue and PBMCs was
extracted and cDNA synthesised as described above.
Selection of primers for expression analysis
The ARs primers for RT-PCR were designed based on the
complete (A2A), predicted (A1, A2B) or partial cd sequences (A3)
(GenBank accession numbers: NM_001081897, XM_001496410,
XM_001918390 and AY_011243, respectively). Primers were
selected for RT-PCR performance and absence of artifacts. The
© 2011 EVJ Ltd
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specificity of the amplified product was confirmed by sequencing.
Amplification efficiency was calculated based on the CT values
obtained from a serial dilution of a positive control cDNA (90–
110%). Sequences for A1, A2A, A2B and A3-ARs, IL-6 and GAPDH
primers and their expected product lengths are listed in Table 1.
PCR reactions with these primers yielded single bands of the
expected sizes. No unspecific secondary primer bands were
observed (Supplementary Fig S1).
Quantitative real-time polymerase chain reaction (RT-PCR)
One mg cDNA was amplified in a 20 ml PCR reaction containing
10 ml of SYBR green supermix8 and 10 mmol/l of forward and
reverse primers. The PCR was performed in the iCycle IQ
multicolour real time PCR detection system8 with an initial
incubation step at 95°C for 10 min to activate the enzyme and
45 cycles of amplification, including a denaturation at 95°C for
15 s and a 1 min extension at 60°C. Samples without cDNA were
always included in the amplification reactions to check for
contamination. All reactions were performed in triplicates. Fold
changes in the expression of each gene was calculated using
the 2-DDCT method (Livak and Schmittgen 2001), with the
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcript
as an internal standard. Relative AR and IL-6 levels in resting
cells are expressed as the ratio of the CT value for the gene of
interest/CT for GAPDH. Mean GAPDH CT values for airway and
control horses are 19.98 and 20.35 (difference not significant), with
coefficients of variation are 3.68 and 3.65%, respectively. Finalised
RT-PCR reactions were loaded in a 2% agarose gel containing
0.1 mg/ml etidium bromide for visualisation of DNA and subjected
to electrophoresis.
Data analysis
Statistical analysis was performed using the PASW Statistics
software9. Data were analysed by nonparametric tests (Mann-
Whitney U test, Spearman correlation coefficient) or with the t test
with Welch correction when values showed normal distribution
(A2BAR expression). Differences between groups were considered
significant when P values were less than 0.05.
Results
Cytological characterisation of BAL samples
Control horses had cytological values within physiological
range (neutrophils <5%, lymphocytes 30% to 60%, macrophages
40–70%, eosinophils <0.5%, basophils <2%), with the exception of
2 horses with a marginal increase of neutrophils and one horse with
high basophil count.
On the contrary, airway-compromised horses showed
significantly higher counts for nondegenerate neutrophils.
Interestingly, 2 horses also had increased eosinophils (Horses 15
and 16, 6.3 and 2.8%, respectively), suggesting that this is a rather
heterogeneous group with varied pathophysiological conditions
and/or disease states. The cytological findings of the horses
included in the study are summarised in Table 2.
Tissue-specific AR expression profiles
RT-PCR analysis from one healthy horse revealed a heterogeneous
expression profile for the 4 AR subtypes across the tissues
explored. The RT-PCR reactions were loaded on an agarose gel
(Fig 1a) and analysed quantitatively (Fig 1b). Product length,
specificity and the absence of primer-dimer products were
confirmed in BAL cells and cerebellum (Supplementary Fig S1).
WhileA1AR could not be detected in BAL–recovered cells, this
AR was expressed both in cerebellum and cortex, jejunum, caecum
and eye. Exceptionally high A1AR levels were detected in fat, in
agreement with previous reports showing that this subtype is
heavily expressed in this tissue, mediating most of the effects
of adenosine on adipocytes (Kaartinen et al. 1991). A2AAR could
be detected in all samples, although levels were very low in
cerebellum, cortex and kidney. Significant levels of this AR were
identified in spleen (where it was the predominant AR type), in
adrenal and in myocardium, while high levels were detected in
PBMCs. Among all ARs, the A2B subtype was the most commonly
detected. Expression in PBMCs was very prominent, with high
levels in BAL cells and cerebellum, and intermediate in cortex,
aorta and adrenal gland. A2BAR transcripts were less abundant in
myocardium, stomach, spleen, fat and eye. In contrast, expression
of the A3AR was less common, with highest levels in PBMCs
and lower ones in BAL cells, jejunum, adrenal, fat and eye.
Interestingly, the expression pattern in PBMCs was similar to that
of BAL-cells, but with overall expression values about 10-fold
higher than BAL.
AR expression in BAL cells from airway-compromised and
healthy horses
Studies examining the expression of ARs in asthmatics and COPD
patients support the hypothesis of a fundamental alteration in
adenosine signalling in these patients (Varani et al. 2006). The
analysis presented here revealed A2BAR as the predominant
subtype in equine BAL cells, with lower levels of A2AAR and
marginal A3AR expression. Therefore, we wanted to assess the
expression pattern of ARs in BAL from airway-compromised
horses as compared to healthy controls. Although the differences in
A2AAR and A2BAR expression between both groups were not
significant, a tendency for decreased A2BAR expression in airway-
TABLE 1: Primer sequences and expected product lengths of the genes analysed
Gene GenBank accession No. Forward primer (5′-3′) Reverse primer (5′-3′) Product length (bp)
A1AR XM_001496410 TCAACATCGGGCCACGGACC CAGGTTGTTCCAGCCAAACAGAG 242
A2AAR NM_001081897 CGCGAGTTCCGCCACACCTT CCTGCTCTGCATCGCTGCCA 124
A2BAR XM_001918390 TCACDCAGAGCTCCATCTTC CAAAGGCAAGGACCCAGAGG 141
A3AR AY_011243 AGGGACACAGGAAGCCAGCTCA GGAAGCCCTGCAGCTTCTGTTCC 213
IL-6 NM_001082496 ATGAGTGGCTGAAGAACACAACAAC AGGAATGCCCATGAACTACAACAAT 131
GAPDH NM_001163856 TGGCATGGCCTTCCGTGTCC GCCCTCCGATGCCTGCTTCAC 118
© 2011 EVJ Ltd
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compromised horses was observed (Fig 2, P = 0.084). This trend
is in agreement with data from human with chronic airway
inflammation who exhibit lower A2BAR expression, suggesting a
role for adenosinergic signalling in equine airway disease. Note
that A1AR was not detected in any BAL samples and that A3AR
expression levels were marginal in both groups (not shown).
Induction of IL-6 by the adenosine analogue NECA
Based on these observations, we wanted to determine whether AR
activation could trigger the expression of inflammatory cytokines
in BAL-cells. Because IL-6 is a major inflammatory cytokine
regulated by several stimuli, we decided to investigate whether AR
engagement could affect its expression in BAL cells. First, we
determined IL-6 baseline expression levels in all samples relative
to those of GAPDH. Figure 3a shows expression levels in
nonstimulated cells from airway-compromised and from healthy
controls. IL-6 mRNA abundance did not differ significantly
between both groups. Furthermore, RT-PCR cycle numbers for this
cytokine in both groups were close to threshold of detection (cycle
35), implying that IL-6 was minimally transcribed in resting cells
from either group.
Subsequently, the cells were treated for 3 hwith the nonselective
AR agonist NECA and IL-6 induction reassessed (Fig 3b). While
cells from healthy controls failed to upregulate this cytokine
(1.54-fold, not significant), stimulation of cells from airway-
compromised horses resulted in a significant increase of IL-6
transcript (2.51-fold), which was maximal at this time point. This
increase in IL-6 expression in NECA-stimulated BAL cells from
diseased horses was significantly greater than that of control horses
(P<0.01). This suggests that BAL-cells from affected animals
differentially react to the endogenous nucleoside adenosine.
Differential induction of IL-6 in BAL-recovered cells by
AR-subtypes
The A2AAR subtype has been linked with anti-inflammatory
functions at several levels and it has been suggested to be a critical
part in negative feedback mechanisms for the limitation and
termination of inflammatory responses (Ohta and Sitkovsky
2001). Therefore, we wanted to assess the role of this receptor
subtype in inflammatory disease in equine airways. More
precisely, our aim was to determine whether activation of this
AR-subtype could influence adenosinergic proinflammatory
signalling in BAL-recovered cells. Therefore, we first tested
whether A2AAR activation could influence IL-6 expression. As
expected, activation of A2AAR with the selective agonist CGS-
21680, at a concentration that has been shown to effectively
inhibit LPS-mediated ROS production in equine neutrophils (Sun
et al. 2007), did not induce IL-6 expression in BAL cells either
from airway-compromised or healthy controls (Fig 4a). Further,
we evaluated whether A2AAR blockage could influence IL-6
upregulation by NECA, by treating cells with a combination of
NECA plus the A2AAR antagonist SCH-58261. Because this is
the first study in which equine cells are exposed to SCH-58261
the concentration of 1 mmol/l was extrapolated from binding
studies in rat and bovine tissues and functional assays in rabbit
and porcine systems (Zocchi et al. 1996). While SCH-58261 did
not affect IL-6 expression, the combined treatment of NECA and
SCH-58261 resulted in a moderate but significant increase of
IL-6 expression in healthy controls (median 5.28; s.d. = 1.96),
when compared to NECA alone. Similarly, A2AAR blockage in
airway-affected horses resulted in prominent increases in IL-6
induction by NECA, reaching up to 29-fold upregulation (median
= 13.04; s.d. = 7.84). In addition, IL-6 upregulation by combined
NECA and SCH-58261 treatment was significantly different
between both groups (Fig 4a). Altogether, this data shows that
activation of A2AAR in BAL-recovered cells can modulate
proinflammatory signalling by other ARs, particularly in airway-
affected horses.
Finally, we examined whether this differential IL-6 induction
by AR activation could be associated with the changes in BAL
cytology. Indeed, we detected a correlation between neutrophil
count and IL-6 induction by NECA plus SCH-58261 for all 18
horses included in this study (Fig 4b), suggesting a causal
relationship between the neutrophil number and AR-dependent
TABLE 2: Cytological ﬁndings in BAL cells from healthy (1–10) and airway-compromised horses (11–18)
Horse Sex Age
Neutrophils
(%)
Lymphocytes
(%)
Macrophages
(%)
Eosinophils
(%)
Basophils
(%)
1 F 10 1.3 45.9 52.1 0.7 0
2 M 17 1.9 52.2 45.4 0 0.5
3 M 5 5.7 56.3 36.8 0 1.2
4 F 15 6.1 69.3 24.2 0 0.4
5 M 5 0.8 48.9 46.8 0 3.5
6 F 8 2.1 41.6 55.2 0 1.1
7 M 16 3.4 62.4 33.3 0 0.9
8 M 9 0.5 60.5 37 0.5 1.5
9 M 5 3.5 57.9 38.2 0 0.4
10 F 6 1.8 47.6 49.8 0.3 0.5
Median (min, max) 2.7 (0.5, 6.1)* 54.3 (41.6, 69.3) 41.8 (24.3, 55.2) 0.2 (0, 0.7) 0.7 (0, 3.5)
11 M 5 5.3 49.3 43.9 0 1.5
12 F 13 50 23.9 25.7 0 0.4
13 F 6 12.6 48 37.4 0 2
14 M 17 5.8 38.7 55.5 0 0
15 M 18 16.7 43.4 30.8 6.3 2.8
16 M 16 5.6 30.1 60.6 2.8 0.9
17 F 10 12.8 51.4 34.5 0.7 0.7
18 M 16 26.5 48.1 22.7 0 2.7
Median (min, max) 12.7 (5.3, 50)* 45.7 (23.9, 51.4) 36 (22.7, 60.6) 0 (0, 6.3) 1.2 (0, 2.8)
*P0.01 (Mann Whitney test).
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IL-6 induction. A similar correlation was observed with IL-6
induction by NECA (not shown).
Discussion
In this study we first characterised the expression of adenosine
receptors in BAL samples, as compared to other tissues. Besides
the tissue-specific variations that hint towards divergent
adenosinergic pathways in different organs and systems, whose
interpretation exceeds the scope of this study, we observed a
remarkable similarity between the AR profiles of BAL-cells and
PBMCs. A2BAR was predominantly expressed in both of these cell
types, followed by A2AAR and lower A3AR levels. This analogy
and the fact that neutrophils express primarily A3AR (Varani
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Fig 1: Expression profiles of ARs in tissue samples from a single healthy horse, assessed by RT-PCR. a) Finalised reactions (cycle 45) were loaded in an
agarose gel for side by side for comparison. GAPDH reactions are included as a loading control. ML: DNA molecular ladder, sizes are given in base pairs.
b) Quantitative analysis. The values are relative to GAPDH and indicate mean and standard deviation of 3 independent measurements.
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Fig 2: AR expression in BAL-samples from airway-compromised and
control horses, by RT-PCR. Expression values are relative to GAPDH and
indicate mean and standard deviation of 3 independent measurements (t test
with Welch correction).
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et al. 2009) insinuate that lymphocytes and macrophages are the
predominant AR-expressing cells in BAL (together they represent
over 90% of BAL cells). Furthermore, these observations suggest
that adenosine could play an immunomodulatory function in the
airways in the horse.
In line with this hypothesis, we show enhanced reactivity
of BAL-cells from airway-compromised horses upon ex vivo
AR stimulation, thereby establishing a link between adenosine
signalling and airway inflammation in this species. RT-PCR
analysis revealed increased expression of IL-6 upon nonselective
AR activation with the adenosine analogue NECA in cells from
airway-affected horses, while this response was absent in control
animals. This amplified response to adenosine could be explained
by adaptive responses of airway/BAL-cells to the inflammatory
milieu. Long-term in vitro exposure studies have indeed shown
desensitisation of ARs by adenosine in target cells (Fredholm et al.
2001). In COPD patients, for example, elevated concentrations of
adenosine and other inflammatory mediators in the peripheral lung
tissue correlated with downregulation of the A2BAR and with
increased densities of theA2A andA3AR (Varani et al. 2006). In line
with that report we detected a trend towards a decrease inA2BAR in
airway-affected horses, which was not significant (possibly
because of the heterogeneity in AR expression, particularly among
healthy horses). A systematic analysis of AR expression by cell
type in a larger sample group would be necessary to confirm of
this trend.
The exaggerated response of airway-affected horses can also
be explained by the alterations in their BAL cytology. In fact, we
identified a correlation between percentage of neutrophils in BAL
and cell reactivity to adenosinergic proinflammatory signalling.
This observation, however, does not allow to establish whether IL-6
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Fig 3: a) Expression of IL-6 in resting, nonstimulated BAL cells. cDNA was
obtained from each horse and IL-6 abundance assessed by RT-PCR.
Expression values are relative to GAPDH. b) Induction of IL-6 by NECA in
BAL cells. Values for each reaction were normalised against GAPDH and
fold changes calculated in relation to basal values for each horse (resting
cells). Whiskers represent 10 and 90 percentiles. *: P0.01 vs. basal values
and between groups (Mann-Whitney U test).
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upregulation depends on neutrophil count, or, on the contrary,
whether higher neutrophils in BAL are the result of increased
proinflammatory AR signalling with elevated levels of IL-6 and
probably of other neutrophil chemotactic factors.
IL-6 is a multifunctional cytokine that has been associated with
inflammation and the development of immune responses. Although
initially considered a surrogate marker of inflammation (similar to
IL-1b and TNF-a) it is now clear that IL-6 can also influence the
effector functions of various CD4+ T cell subsets. IL-6 inhibits Th1
differentiation and promotes Th2 differentiation during early
CD4+ T cell activation, and also induces the differentiation of
Th17 effector cells in the presence of TGF-b (Mangan et al. 2006).
IL-6 also inhibits regulatory T cell development, most likely by
suppressing Foxp3 expression (Dominitzki et al. 2007). Its role in
promoting Th2 and Th17 differentiation, along with inhibiting
regulatory T cell activity, suggests that IL-6 might play a role in the
onset and/or progression of diseases associated with these types of
immune responses, including RAO. Interestingly, engagement of
proinflammatory ARs has been linked to increased release of IL-6
from epithelial cells, astrocytes and fibroblasts (Sitaraman et al.
2001; Zhong et al. 2005). In addition, a recent study using Calu-3
human epithelial cells demonstrated that extracellular adenosine
induces a robust release of IL-6, establishing a connection between
adenosine and neutrophil infiltration in the airway lumen (Sun
et al. 2008b).
Activation of A2AAR has been associated to anti-inflammatory
effects, including modulation of neutrophil and mast cell activation
and degranulation, downregulation of oxidative species and
adhesion molecules and inhibition of cytokine release (Lappas
et al. 2005). In the lung, activation of the A2AAR was linked to
downregulation of inflammation in models of allergic asthma
(Koshiba et al. 1999; Fozard et al. 2002). A2AAR activation also
attenuated IL-6 levels associated with inflammatory lung injury in
a rat model for cardiopulmonary bypass (Mohsenin et al. 2007)
and recent evidence indicates this AR can modulate inflammatory
signals in the horse. For example, activation of the equineA2AAR in
a heterologous system was shown to inhibit the proinflammatory
factor NF-kB (Sun et al. 2008a). Also, engagement of A2AAR on
LPS-activated equine peripheral blood monocytes led to a decrease
in expression of COX-2 and TNF-a and upregulation of IL-8
and IL-10, implying a role of this receptor in the modulation of
inflammatory signals (Sun et al. 2010). Here, we investigated for
the first time the role ofA2AAR in the airways. Selective blockage of
theA2AAR in BAL-cells with SCH-58261 allowed us to distinguish
between the effect of this receptor subtype and the composite effect
of all ARs by NECA, thereby revealing the existence of functional
A2AAR in equine airways. Because activation of nonA2AARs
in BAL cells with NECA plus SCH-58261 resulted in exaggerated
IL-6 transcription, it can be reasoned that A2AAR downregulates
the induction of the proinflammatory IL-6 induction by the other
ARs expressed in these cells (mainly A2BAR). This effect on the
expression of this proinflammatory cytokine supports the idea of
selective pharmacological activation of A2AAR as a therapeutic
principle in airway inflammation in the horse.
In summary, this study shows that IL-6 is rapidly induced in
BAL-cells of airway-compromised horses in response to adenosine
exposure, probably through A2BAR activation and that this effect
can be modulated by A2AAR. Further analysis of the effect of
A2AAR activation on other inflammatory stimuli will be required
for a more complete assessment of the therapeutic potential of
selective AR activation in the horse.
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